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Abstract
Germline BRCA mutations underlay a significant risk for breast and ovarian cancer
that increases in age. BRCA mutations are usually associated with the most aggressive
subtypes of these cancers such as triple negative breast cancer and high-grade serous
ovarian cancer. Conventional chemotherapeutic or hormonal therapies do not address the
molecular deficiencies responsible for their resistance and there is a high rate of
recurrence. Targeted therapy that can address the unique molecular features in these
subtypes of cancer is the only way to cure the disease or, at the very least, improve
patients’ quality of life.
Homologous recombination repair is an accurate repair pathway that utilizes a copy
of a homologous sequence to relay information to the break site. Cancer cells copy their
DNA extensively meeting the principle demand for this high-fidelity repair pathway.
Homologous recombination repair is utilized by cancer cells to cope with the most
challenging forms of DNA damage such as DNA double strand breaks, stalled replication
forks, adducts, and interstrand crosslinks. Among the key proteins in homologous
recombination repair, RAD52 activity promotes cancer cells’ tolerance and survival.
Therefore, there is a therapeutic opportunity in inhibiting RAD52 activity to push DNA
damage levels in homologous recombination repair-deficient tumors beyond the limits of
viability.
One of the early events in this repair is resection of the broken strand and generation
of single strand DNA. Replication protein A cover and protect those strands and interact
with key DNA repair proteins. RAD52 activity in DNA repair is dependent on its

interaction with replication protein A. The hypothesis of this thesis is that it is possible to
inhibit RAD52 activity by inhibiting its interaction with RPA and this inhibition will
have therapeutic benefits for cancer patients. We explored the binding activity and
affinity of the RAD52 interaction with RPA. Kinetic, and thermodynamic parameters
dictating this protein:protein interaction were measured. The characterization of
RAD52:RPA interaction data guided remapping of the RPA interaction domains on
RAD52. To target RAD52 activity by inhibiting its interaction with RPA, we designed an
in vitro fluorescent-based protein-protein interaction assay. This assay was further
optimized for high throughput settings with a robust signal, minimal steps, statistical
accuracy, and low cost. We screened over 100,000 compounds to look for small molecule
inhibitors. Eleven hits were found and five were selected for their high EC50 values.
Three of the five hits are FDA approved drugs and were selected for cytotoxicity tests in
BRCA-deficient cell lines.
The outcome of our characterization for these three candidate small molecule
inhibitors may shed light on the variation of their efficacy and sensitivity among breast or
ovarian cancer patients with BRCA-defective pathway versus those with none.
Additionally, we present fluorescent-based protein-protein interaction assay as an
affordable method to detect many protein:protein interactions in low-scale or high
throughput settings applicable to finding small molecule inhibitors or aptamer modulators
for protein:protein interactions.
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Chapter 1
1.1. Introduction

2

1.1.1. Normal cell division and DNA damage repair machinery. Regulation of cell
division is essential for tissue homeostasis. This regulation involves utilization of
molecular signals and critical decision-making regulated at discrete stages of a cell’s
lifecycle [1]. A major driver of this decision-making process is DNA damage due to
metabolic or environmental insults. Cells response in the face of these challenges
involves initiating DNA repair processes while activating cell cycle checkpoints to allow
the time needed for repair. Ataxia telangiectasia mutated (ATM), AT and Rad3-related
(ATR), and DNA-dependent protein kinase, for example, are kinases that regulate the
DNA damage response by establishing phosphorylation cascades in cell cycle checkpoint
kinases and support the initiation progression of the appropriate repair mechanisms [2-4].
Cells resort to apoptosis when the damage is beyond their repair capacity [5]. DNA repair
pathways have a common capacity of repairing DNA lesions but vary in their efficiency
as a function of the site, nature of the lesion, cell’s genotype, stage in the cell cycle, and
the risk of mutagenesis in the process. Figure 1.1 summarizes the different DNA lesions
and corresponding specialized repair pathways [6].
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Figure 1.1 Types of DNA damages and repair mechanism. DNA is damaged in various ways
during normal metabolism or by exogenous factors. The top panel of boxes show the types of DNA
damage and arrows point down to specialized repair systems. DSBs are repaired through NHEJ or
HR. The beneficial outcome of different repair pathways is measured by promoting cell survival and
variation in that is indicated by the number of upward arrows. Accurate repair pathways such as HR
are least mutagenic and that is indicated by an upward arrow. Less accurate repairs are mutagenic and
indicated by a downward arrow. BER is involved with small DNA adducts. Transcription-coupled
repair (TCR) deals with lesions that block elongating RNA polymerase. Transcription-coupled
nucleotide-excision repair (TC-NER) repairs transcription-blocking bulky adducts. The path of DNA
polymerases can be stalled due to encountered adducts or cross-links. Such damage can be repaired,
bypassed (template switching or translational synthesis). Figure is adapted from Jan Hoeijmakers,
2009: The New England Journal of Medicine.
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The level of challenge for the cell to repair DNA damage varies. For example, DNA
single strand breaks are frequent but relatively undemanding. These breaks are ligated
either directly within the phosphodiester backbone or after removal of abnormal
structures with as the intact strand holding the ends together [7]. Single strand breaks are
inevitable intermediates in base excision repair BER, nucleotide excision repair NER,
and mismatch repair MMR are among the main DNA repair pathways.
The most taxing form of DNA damage in a cell is the DNA DSB [6]. DSBs are an
unavoidable consequence for a number of physiological processes such as the process of
relaxing DNA supercoils, or during normal cell death by apoptosis [8]. Generally, the
availability of a template on a sister chromatid makes it possible to search for
homologous or near-homologous sequence to copy information accurately in HRR
pathway. This is possible when damage occurs during the S or G2 phase of the cell cycle,
otherwise nonhomologous end joining (NHEJ) is an error-prone alternative repair choice
for non-proliferative cells in G0 and G1 [9, 10]. NHEJ simply involves alignment and
ligation of broken strands. Lahav’s and coworkers avoided the approach of fixing cells
after damage to measure the type of repair activity in relation to cell cycle phase. Instead,
they employed long-term, time-lapse microscopy and fluorescent reporters to obtain
quantitative data that suggested a direct link between HRR and increased active
replication events (Figure 1.2) [11]. Therefore, they argued that it is not the availability of
replicated DNA that dictates the transition to HRR, but rather the extent of active
replication. Single strand annealing (SSA) is another repair process for DSBs occurring at
site of already existing homology, in particular repetitive DNA sequences [12].
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Figure 1.2 Repair choice by HRR or NHEJ and cell cycle. 53BP1 is a DNA damage
response protein which forms subnuclear compartments called foci that provide experimental
assessment of DSBs in cells. RAD52 is a protein that forms foci at DSB sites that are
committed to HRR. (A) Heat map showing the proportion of DSBs repaired by HR (RAD52mCherry foci) post damage (53BP1-YFP foci) shown as a function of the time (hours) from
the induction of DSBs and cell-cycle progression (gray bar on the left). Higher proportion of
HRR activity is observed (red color) with longer extent in replication phases of cell cycle.
(B) The proportion of DSBs repaired by HRR in individual cells post damage is plotted
against their cell-cycle progression at the time of damage indicated by the reference bar on
top. The three lines shown are the median (black line), 25th, and 75th percentile (dashed blue
lines above and below the black line).
(C) Relative accumulation of RAD52 foci in individual cells after damage is plotted against
cell-cycle progression. The three lines shown are the median (black line), 25th, and
75th percentile (dashed blue lines above and below the black line).
(G) A model summarizing collective data from time-lapse microscopy and fluorescent
reporters and represents the transition between NHEJ and HR with cell-cycle progression. In
G1, DSBs are exclusively repaired by NHEJ. HRR activity gradually increase as cells
progress into early S phase and a peak is reached by mid S phase. HRR then decreases
gradually as cells progress toward late S and G2. Cells in late G2 repair their DSBs almost
entirely by NHEJ.
Figure is adapted and modified from Karanam et al., 2012: Molecular Cell.

8

1.1.2. The tolerance for DNA damage by cancer cells. Cancer cells usually exhibit an
abnormal extent of active replication with a large capacity to divide and replicate their
DNA [13]. Accompanying these events is a heavy load of genotoxic stress that when
combined with cytotoxic treatments, results in an intensified amount of DNA damage
mostly in the form of DSBs. Stalled replication forks, interstrand crosslinks, and adducts
are prevalent in the stressful tumor environment and tend to induce more DSBs. At this
level, normal cells would have exhausted their repair capacity mechanisms and resorted
to cell death to prevent the propagation of damage and preserve genomic stability. Cancer
cells on the other hand are not only able to survive, but also are propelled into further
expansion. Resistance to cell death becomes a hallmark for them and they acquire the
ability to maintain the status quo by tolerance for genomic instability [14].
1.1.3. The rise of malignancies and the vision for targeted therapy. The vitality of a
tissue is judged by the ability of its cells to divide with orchestrated control throughout its
life cycle. Cells differentiate into their fateful identity through a tightly regulated process.
This is no surprise, given that a vast portion of our genome encodes regulatory elements
and a much smaller part encodes functional proteins. Although this may seem to be a
rigid process, we now know that a degree of plasticity is offered by our chromatin
structure and associated transcriptional regulators. For example, studies have shown that
in the face of some challenges, the responsibility of DNA replication can be handed over
to other classes of DNA polymerases with more malleable base-pairing capacity [15].
This plasticity allows for an appropriate and adaptive response to environmental or
metabolic stimuli. Flavahan and colleagues postulated that when a cell is faced with a
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challenge, this plasticity allows it to assume alternative functional and regulatory
pathways [14]. For example, cells can shift DNA damage response or repair to alternative
mechanisms or pathways [16]. While these alternative pathways may contribute to a
cell’s fitness in the face of potentially pro-oncogenic stimuli, some can drive the cell into
malignancy. This unfortunate consequence itself gives cancer cells distinctive molecular
features when compared to normal ones, a concept of great importance to researchers
interested in shifting cancer therapeutics to specific and targeted approaches.
Current promising therapies involve targeting pathways that are vital to cancer cells’
survival, proliferation, and the maintenance of their tumor microenvironment [17].
Components of the DNA damage response are at the center of these processes and are,
not surprisingly, among the most frequently mutated in cancer [18]. Evidence includes
the acceleration of hepatocarcinogenesis by constitutive upregulation of different DNA
repair pathways [19], the upregulation of the HRR component RAD51 [20-22], or the
downregulation of tumor suppressors BRCA1/2 [23] in driving breast and ovarian
cancers.
1.1.4. Homologous recombination repair machinery. HRR is initiated by a resection
process at the DSB site in a 5′-3′ direction by the Mre11-RAD50-NBS1 (MRN) complex
producing exposed ssDNA on opposite ends of the break site (Figure 1.3, step 1, 2, and 3)
[24]. This outcome is immediately addressed by replication protein A (RPA) binding
ssDNA at the break site. Aside from physical shielding and protection, RPA contributes
to an accurate repair choice by preventing insufficient homologies to lead the repair
process or haphazard end joining [25]. In addition, RPA prevents the formation of DNA
secondary structures during replication and repair, thereby contributing to the
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maintenance of genomic stability [26, 27]. This role for RPA continues until RAD51
takes over the repair process by forming presynaptic filaments to catalyze homologous
strand invasion and annealing [28]. An active ongoing HRR is usually experimentally
observed in the form of discrete subnuclear structures called RAD51 foci [29]. The
replacement of RPA with RAD51 requires a mediator protein.
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Figure 1.3 HRR and BRCAness. A schematic representation of the repair steps of
DSBs by HR. Tumor suppressor proteins involved in the process are shown in bold.
BRCA1 is an example of those proteins and is essential for the early step in repair where
MRE11A-NBS1–RAD50 (MRN) complex detects and bind broken strands. This
complex, along with recruited ATM, leads the resection process and generation of
ssDNA on either side of the break. The next tumor suppressor proteins in the process is
BRCA2, which localizes RAD51 to the exposed ssDNA regions to perform homology
search. PALB2 is an additional tumor suppressor that is crucial for the localization of
BRCA2. Next, nucleoprotein filament formed by RAD52 recombinase invade an intact
DNA double helix containing a homologous, sequence (indicated in red). This sequence
is used by DNA polymerases as a template to synthesize new DNA that repair the break.
Finally, resulting cross-over structures are resolved by DNA ligases and endonucleases.
Blue branching boxes on the right represent the vulnerabilities of cells with defected
HRR and ways to exploit that vulnerabilities in targeted therapy. For example,
pharmacological inhibition of PARP leads to accumulation of DSBs that cannot be
efficiently repair by HR when BRCA1, PALB2, or BRCA2 are mutated. Also, loss of
HRR probably cause shunting of DSBs repair to alternative mutagenic DNA repair
pathways such as NHEJ resulting in gross chromosomal instability and cell death. Figure
is adapted from Lord and Ashworth, 2016: Nature Reviews Cancer.

13

1.1.5. The status of BRCA1/2 in RAD51-mediated HRR. BRCA1 and BRCA2 play a
crucial role in both detection and repair of DSBs. BRCA2 joins BRCA1 in a complex that
co-localizes with RAD51 and activates DSB repair [30, 31]. BRCA1 is implicated in
regulating the activities of the DNA repair by HRR such as the formation and function of
the MRN complex (Figure 1.3, step 3) [32-34].
While BRCA1 function in HRR is focused on recruitment, activation, and assembly
of repair components, BRCA2 plays a more direct role. For RAD51 subunits to load and
nucleate a protein filament on the ssDNA strands, RPA must be displaced. In eukaryotes,
the BRCA2 proteins are the main mediators of this process [35]. Heyer and colleagues
have shown that BRCA2 plays an integral role in HRR not only as a mediator, but as a
driver of the process as it stimulates RAD51 binding to ssDNA [36]. In fact, direct
interaction and regulation of RAD51 repair activities defines the role of BRCA2 in
HRR(Figure 1.3, step 4) [37].
1.1.6. The significance of ‘BRCAness’ in cancer. Germline mutations in the tumor
suppressor BRCA1, BRCA2, or PALP2 are associated with the majority of hereditary
breast and ovarian cancers [38, 39] and contribute, less frequently, to the risk for prostate,
pancreas, fallopian tube, bile duct, stomach, and male breast cancer [40-43]. Moreover,
BRCA1 was identified as FANCS while BRCA2 as FANCD comprising the Fanconi
anemia-BRCA pathway. Mutations are also associated with predisposition to acute
myelogenous leukemia and epithelial cancers [44-46]. In a broad sense, BRCAness is
defined as defect in DSBs repair by HR. Figure 1.3 depicts DSBs repair by HR and the
significance BRCA1, BRCA2, and PALP2 in the process [34]. Tumors with BRCAness
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share molecular features across their different subtypes [47]. Hallmarks of BRCAness’
include basal-like phenotype, ER-negativity, EGFR expression, sensitivity to DNAcrosslinking agents, and loss of RAD51 foci formation [48]. BRCAness predisposes
women to the most aggressive subtypes such as triple-negative breast cancer (TNBC)
[49]. The majority of high-grade serous carcinoma (HGSC), which account for over half
of all ovarian epithelial tumors with the lowest survival rate, demonstrate BRCAness
[50]. TNBC and HGSC remain challenging in the face of available conventional hormone
or cytotoxic chemical therapies due to lack of hormone receptors, poor prognosis, and
high rate of recurrence [51, 52]. Due to the significance of the BRCAs in DSB repair,
exploiting their malfunctions can offer selective killing of cancer cells.
1.1.7. The status of RAD52 in RAD51-mediated homologous recombination repair.
Knowing the indispensable role of Rad52 and its epistasis group of genes in HRR in
Saccharomyces cerevisiae, West and colleagues were motivated to investigate its status
in human HRR. Accordingly, they developed an in vitro system using purified human
RPA, RAD51, and RAD52 proteins to reconstitute the HRR processing of DSBs. In
addition to their detailed finding of the overall repair process, RAD52 was found to
function in stimulating RAD51 interaction with ssDNA [53]. However, the significance
of RAD52 remained perplexing as two in vivo model studies at that time showed the
unhampered ability of mammalian cells to mount an HRR response in the absence of a
functional RAD52. The first of these studies measured the number of RAD51 foci after
gamma-irradiation of normal verses. RAD52-/- in the DT40 chicken B cell lines [54]. No
difference was found in the formation or cycling of RAD51 foci indicating an unhindered
HRR process. Another independent study found that RAD52 knock-out mice were
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aphenotypic and relatively similar in their ability to mount HRR compared to mice with
wild-type RAD52 [55]. Interest in RAD52 function in DSB repair eventually sparked
with the series of siRNA targeting studies by Simon Powell and collaborators that
demonstrated dependence of cells deficient in BRCA2 function on RAD52 to carry
RAD51-mediated HRR of DSBs [56]. RAD52 indeed is capable of taking over this
BRCA2 function in HRR given its reported direct interaction with RAD51 [57]. In fact, a
synthetic lethal relationship was concluded to exist between RAD52 and BRCA2 as well
as BRCA1 and PALB2 as explained in the next section [58].
1.1.8. BRCA proteins & RAD52: Synthetic lethality relationship. In the face of
mounting DNA damage challenges cancer cells become “addicted” to DNA repair
pathways. These alternative pathways are usually not the same ones that led to their
malignant phenotype. Having lost the function of their main DNA repair pathway(s) by
oncogenic alterations, selective cell death can be achieved by toxic accumulation of DNA
damage when the alternate pathway(s) is targeted by an inhibiting or a modulating agent.
Cancer cells deficient in BRCA1/2 function show reliance on RAD52 to mediate
RAD51-facilitated HRR and SSA of DSBs [59-61]. These findings motivated a number
of studies aimed at targeted cancer therapy exploiting the synthetic relationship between
the BRCAs and RAD52. Indeed Cramer-Morales and colleagues demonstrated potential
targeted therapeutic effects in leukemia cells harboring impaired BRCA1 function by
targeting RAD52 activity [60]. A number of similar efforts followed to find ways to
inhibit RAD52 to induce selective cell death in BRCA-deficient tumors and recently
reviewed by Spies et al.[62-65].
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1.1.9. RAD52 and tumorigenesis, beyond filling-in for BRCA2. Targeted therapy
efforts rely on identifying specific molecular factors that enable tumor cell survival and
growth. Recent expanded understanding of RAD52 activity suggests that it can assume
“emergency” roles and is specifically recruited to DNA replication stress sites [66].
Therefore, RAD52 appears to promote tumorigenesis extending beyond the narrow scope
of providing a backup pathway in BRCA-deficient cells. For example, RAD52
upregulation was reported in liver cancer [19] and RAD52 is required for the recovery of
a collapsed replication fork [67, 68]. RAD52 is also the main player in SSA, a repair
process that was reported to increase in some cancers [69]. Moreover, some cancerassociated genes are reported to be enriched for repetitive sequences suggesting
potentially increased SSA activity [70]. SSA repair activity of DSBs was also observed to
increase in response to general decrease in RAD51-mediated HRR [71].
Recently a new inverse strand exchange activity for RAD52 was identified to drive
RNA-templated DSBs repair [72]. It is no surprise, therefore, that targeting RAD52
activity was not only selectively lethal to BRCA-deficient cell [56], but also suppressed
cancer stem and progenitor cell expansion [60], and even augmented the activity of the
tumor immune response [73].
1.1.10. Approach to target RAD52 repair activity. RAD52 function has been
correlated with several stress-induced responses that foster survival during uncontrolled
cell growth. Targeting RAD52 is detrimental to BRCA-deficient tumors and may very
well deprive other types of tumor microenvironments of an essential survival and
maintenance factor. Different SMIs and aptamers have been identified and developed
however, the common goals have been targeting RAD52 interaction with substrate DNA
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and RAD52 annealing activity. Among the early approaches was the targeting of a
residue on the RAD52-DNA binding domain (F79) by an aptamer to achieve synthetic
lethality in chronic myelogenous leukemia cells deficient in BRCA1 activity [60]. More
work followed to find a SMI to disrupt the ring structure of RAD52 and prevent the
formation of the presumed ssDNA-binding grooves [74], RAD52 SSA repair activity of
DNA [63], and inhibition of RAD52-ssDNA inhibitors [62, 64]. The outcomes of these
studies are promising and motivating, however, our expertise in DNA repair proteins
suggests for a different approach.
Aside from the innate ssDNA annealing capability demonstrated in vitro by
Sugiyama and colleagues [75], all RAD52 repair activities described earlier require
interaction with RPA. Given its abundance [76] and high intrinsic affinity for ssDNA
[77], any single stranded region formed is immediately bound by RPA. This strong hold
of DNA enables RPA to coordinate repair components arriving at the break site. Indeed,
RAD52 function in HRR seems to be dictated by RPA. Early studies demonstrated that a
mutated RPA-binding domain on Rad52 impairs its recruitment to the damage site [78].
We have shown that in the absence of RPA, RAD52 exists in rings and aggregates of
rings and that monomeric RAD52 purifies in a stable complex with RPA-ssDNA. RPA
was capable of promoting the breaking of the RAD52ring structure supporting RPA role
in RAD52 activity [79]. In the recently described role for RAD52 in RNA-templated
DNA DSB repair, the addition of RPA noticeably stimulated the repair activity [72].
Inhibiting RAD52’s interaction with RPA is probably detrimental to all its functions in
repair. The feasibility of this approach, however, has been met with reluctance as it
involves targeting of a PPI with small molecule inhibitors. Among candidate cancer
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targets, PPIs were historically discounted due their large and discontinuous epitopes.
However, protein mutations are among the drivers for tumorigenesis as well as the
development of resistance [80]. Remarkable strides were achieved recently in
pharmaceutical targeting PPI of the Bcl-family of proteins to impede cancer cell survival
[81]. These recent advances have improved the outlook on targeting PPIs for the
development of new therapies.
The hypothesis of this thesis is that RAD52 can be as a targeted through its
interaction with RPA. This PPI constitutes a repair pathway to mediate RAD51 activity in
HR offering a backup survival path in BRCA-deficient tumors. The therapeutic value of
targeting RAD52 activity can apply to several types of tumors. We investigated both
kinetic and thermodynamic parameters of the RAD52:RPA complex deciphering
important domains of interactions. Our work here acknowledges that there are still many
potential targets to explore for targeted therapeutics which raises the need for a reliable
high throughput experimental technique to search for compounds capable of modulating
the function of a target. To address this need and contribute to the efforts, we developed a
PPI assay and utilized it to confirm interacting domains. The assay was optimized for use
in high throughput settings and used to screen over 100,000 small molecules looking for
inhibitors. Finally, we detail our cell-free and cell-based methods characterizing
candidate SMIs to determine their therapeutic value. Characterization results of some hits
show reduced survival of cancer cells when RAD52 interaction with RPA is inhibited and
thus validate the hypothesis.
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Chapter 2
A simple fluorescent assay for the discovery of
protein-protein interaction inhibitors
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2.1. Abstract
Due to the therapeutic potential of targeting PPIs there is a need for easily executed
assays to perform HTS of inhibitors. We have developed and optimized an innovative and
robust fluorescence-based assay for detecting PPI inhibitors, called FluorIA (Fluorescencebased protein-protein Interaction Assay). We use targeting the PPI of RAD52 with RPA as
an example and describe the FluorIA protocol design and optimization for future HTS of
large chemical libraries. Here EGFP-tagged RAD52 detects the PPI using RPA coated,
black microtiter plates and loss in fluorescence intensity identifies SMIs that displace the
EGFP-tagged RAD52. The FluorIA design and protocol can be adapted and applied to
detect PPIs for other protein systems. This should push forward efforts to develop targeted
therapeutics against protein complexes in pathological processes.
2.2. Introduction
High throughput screening (HTS) has evolved into a specialized key drug discovery
tool [82, 83]. With this advancement, the ambitions of scientific research shifted from the
delivery of indiscriminate agents to drugs with more selectivity for the target. Current
targets in cancer, for example, include abnormally expressed proteins, tumor
microenvironment components, and alternative survival pathways adapted by tumor cells
[17]. In each of these categories of therapeutic approaches, targeting pathologic PPIs are
as promising as targeting mutated genes. PPIs orchestrate the signaling of normal cellular
proliferation, the very trait that defines malignancies when deregulated. To sustain chronic
proliferation, cancer cells acquire alternative signaling pathways defined by unique and
specific PPIs [13].
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Modulation of PPI with small molecules was, justifiably, described as “undruggable”
or the “high-hanging fruit” [84]. Over the past two decades, however, interest in targeting
PPIs increased with advanced knowledge of proteomics. Large PPI interfaces, for example,
once regarded as a major challenge to target with small drug-like molecules are now
desirable to bolster selectivity [85, 86]. Also, the community no longer thinks SMIs must
mimic the interacting partner of the targeted protein and this realization led to a more
comprehensive screening of available libraries [87-89]. Mutational studies demonstrated
that only some residues in the PPI, or “hot spots”, contribute the majority of binding energy
for the SMIs to bind and block the targeted protein partner from binding[85, 90]. With this
finding, the quest for targeting PPIs with SMIs became plausible and the development of
robust and cost-effective assays for HTS of SMI libraries for PPIs are in demand.
Successful HTS screens that target PPIs include nuclear magnetic resonance [91],
differential scanning fluorimetry[92], Fluorescence polarization/anisotropy[93], virtual
screening with docking[94] and cell-free, enzyme-linked immunosorbent assay (ELISA)
[95, 96].
Here, we describe our design and optimization of a fluorescent-based protein-protein
interaction assay (FluorIA) applicable for HTS. As an example, we applied our assay to
target the PPI of two important DNA repair proteins: RAD52 and replication protein A
(RPA). RAD52 is a multi-domain protein that mediates homologous recombination repair
of DNA double-strand breaks, a role mainly played by BRCA2 in mammalian cells [36,
97-99]. Tumor cells that have lost BRCA2 function rely on RAD52 to survive the breaks
encountered from replication stress or cytotoxic treatments [61, 100, 101] and this presents
a therapeutic opportunity to target RAD52 activity in BRCA-deficient tumors [56, 58, 60,
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63, 102]. For homologous recombination, breaks are initially processed to produce singlestranded DNA tails that are then bound by RPA. The PPI of RAD52 with RPA is extensive
and essential for RAD52 activity in the subsequent steps of repair [75, 79, 103]. Plate and
co-workers demonstrated by mutational analysis that the ability of RAD52 to form repair
foci required the RPA-binding domain [78]. Since the structure of the RAD52:RPA PPI is
unknown, the FluorIA was developed using full length proteins and designed to screen for
SMIs of the RAD52:RPA PPI in an unbiased manner. The application of this protocol to
other PPI will support quests to find therapeutic SMIs or modulators targeting cancer or
other pathological conditions.
2.3. Materials and methods
2.3.1. Protein expression and purification. The plasmid for full-length RPA (Figure
2.1A) in pET29a vector, a gift from Dr. Marc Wold, was transformed into Rosetta2(DE3)
Escherichia coli with chloramphenicol and kanamycin selection. A single colony was
inoculated into 5 mL starter culture and grown with selection for 6-8 hours at 37 ºC. Large
cultures were made by inoculating 1 mL starter culture into 2 L sterilized LB with
antibiotics in 4 L flasks and incubating at room temperature or 37 ºC overnight without
shaking. The following day, the cultures were incubated at 37 ºC with shaking and induced
with 0.5 mM isopropyl-β-D-l-thiogalactopyranoside (IPTG) at an A600 of 0.6-0.8. After 3
hours, cells were collected by centrifugation at 8,500 xg for 20 min. Pellets were divided
into 5 gram portions and stored frozen at -20 ºC.
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Figure 2.1 Domain maps of proteins used in this study. (A) RPA, (B), RAD52(1303), (C) Full length RAD52 tagged with 6x His EGFP. Structured domains and
flexible linkers indicated as thick and thin boxes respectively.
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Each RPA cell pellet was thawed and resuspended in 25 mL of HI-0 buffer [30 mM
HEPES pH 7.8, 0.25% inositol, 0.25 mM EDTA, and 1mM dithiothreitol] with 500 mM
sodium thiocyanate (NaSCN) plus 250 μL of protease inhibitor cocktail (PIC, Sigma, Cat.
#P8849) before lysis using an Emulsflex-C3. Lysate was clarified by centrifugation at
45,000 xg for 30-45 min. The NaSCN content was reduced by either dilution or dialysis
against HI-0 buffer and then filtered through a 0.45 μm filter. All chromatography steps
employed HI-0 with varying salts. First the lysate was applied to a HiTrap Blue HP column
(5 mL, GE Life Sciences # 17-0412-01) and washed For 5 CVs with 800 mM KCl followed
by 5 CVs with 0.5 M NaSCN and then eluted with 1.5 M NaSCN into 1 mL fractions. The
NaSCN content was reduced by either dilution or dialysis against HI-0 buffer and then
applied to a hydroxyapatite column (3 mL, BioRAD # 157-0040) and eluted in a 25 CV
gradient of 0-75% 160 mM NaPO4. The column was cleaned by washing with 2 M KPO4
in HI-0 after each use. RPA fractions were pooled and diluted with 4 volumes HI-0 before
polishing with a monoQ anion exchange column (1 mL, GE Life Sciences # 17-5166-01).
RPA was eluted in a 25 CV gradient of 0-100% 1 M KCl. Throughout the purification
procedures described above, fractions were examined by 10% polyacrylamide gel
electrophoresis (SDS-PAGE) with Coomassie stain (Figure 2.2). A NanoDrop1000 was
used to measure concentrations using a molecular weight of 110 kDa and ɛ280=87.2 M-1cm1

. Finally, purified RPA was stored at -20 °C in 500 mM KCl in HI-0 with 30% glycerol
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Figure 2.2 Proteins used in FluorIA. SDS-PAGE gel of the purified
proteins.
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The RAD52(1-303) (Figure 2.1B) in pET28b plasmid was a gift from Dr. Min Park. It
has a 6xHis tag on the C-terminus that is not cleavable. Transformation was done into
Rosetta2(DE3). Expression and growth were the same as described for RPA with the
exception of allowing large cultures to cool in an ice bath for 30 min before inducing with
IPTG. Cultures were then transferred to a pre-chilled shaker at 18 ºC for 15-18 hours.
Pellets were processed in the same manner described above.
A thawed RAD52(1-303) cell pellet was resuspended in 25 mL of buffer A [50 mM
Tris-HCl pH 7.8, 300 mM KCl, 2 mM β-mercaptoethanol (β-ME), 10 mM imidazole, and
10% glycerol] with 250 μL of PIC and lysed. Clarified and filtered lysate was then loaded
onto a HisTrap FF column (5 mL, GE Life Sciences). The protein eluted with a 25 CV
gradient to 1 M imidazole in buffer A. Eluted fractions were pooled and dialyzed against
heparin buffer (50 mM Tris-HCl pH 7.5, 200 mM KCl, 2 mM β-ME, 0.5 mM EDTA, and
10% glycerol). The dialyzed protein was loaded onto a HiTrap Heparin HP column (5 mL,
GE Life Sciences) and eluted with a 25 CV gradient to 1 M KCl in heparin buffer. The
recovered protein was dialyzed overnight into a storage buffer (20 mM HEPES pH 6, 400
mM NaCl, 100 mM KCl, 1 mM EDTA, 2 mM β-ME, and 10% glycerol). The protein was
stored frozen with 30% glycerol. A NanoDrop1000 was used to measure concentrations
using a molecular weight of 34.6 kDa and ɛ280=20.4 M-1cm-1. Purity of fractions was
assessed by SDS-PAGE (Figure 2.2).
Full-length RAD52 tagged with 6X-His enhanced green fluorescent protein (EGFPRAD52) (Figure 2.1C and Figure 2.3), in pET28a vector was ordered from GenScript with
codons optimized for E. coli expression and the overall design is described in the
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supplement. BL21(DE3) were transformed and selected with kanamycin. Expression,
growth, and pellet storage was as described for RAD52(1-303). It is noteworthy that
overnight growth at 18 ºC was mandatory for protein expression.
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Note, the F64L\S65T EGFP mutations are highlighted in green and the thrombin cleavage
site is underlined.
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Figure 2.3 Details of EGFP and EGFP-RAD52 expression plasmids and proteins. All
expression plasmids were made by Genscript®. Codons were optimized for expression in
Escherichia coli. Enhanced green fluorescent protein (EGFP) was cloned into the pET28a plasmid
using the NdeI site so that a thrombin cleavable, 6X His tag was placed at the N-terminus. The NTEGFP-RAD52 was cloned into pET28a in a similar manner. For the later construct a disordered
soluble linker was inserted between EGFP and RAD52. Note, the amino acid sequences with a
dotted underline are disordered in the EGFP crystal structure (PDB ID 2Y0G). The soluble
disordered linker has a double underline and the human RAD52 sequence is highlighted in yellow.
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Thawed EGFP-RAD52 cell pellets were resuspended in 25 mL buffer B (50 mM
BICINE pH 9, 300 mM KCl, 200 mM NaCl, 10 mM imidazole, 10% glycerol, and 2 mM
β-ME) with 250 μL of PIC and lysed. The clarified lysate was loaded onto a HisTrap
column and eluted in a 25 CV gradient to 1 M imidazole in buffer B. Keeping the lysate
and buffers ice-cold throughout was necessary to prevent the loss of the EGFP tag from
the protein. A NanoDrop1000 was used to measure concentrations using a molecular
weight of 76 kDa and ɛ280=63.0 M-1cm-1. The protein product was verified by SDS-PAGE
gel (Figure 2.2). The protein solution was then mixed with 30% glycerol and stored at -20
ºC. EGFP-RAD52 must be made fresh the week of HTS.
A plasmid of 6xHis-tagged EGFP in pET28a vector was ordered from GenScript with E.
coli optimized codons and transformed into BL21(DE3) with kanamycin selection.
Expression, growth, and pellet storage was as described for RAD52(1-303). EGFP cells
were resuspended in 25 mL buffer C (50 mM BICINE; pH 9, 20 mM imidazole, 200 mM
NaCl, and 2 mM β-ME) with 50 μL of PIC and lysed. The lysate was loaded onto HisTrap
column and eluted with 25 CV gradient up to 500 mM imidazole in buffer C. The tag was
removed by thrombin digestion to give pure EGFP (Figure 2.2).
2.3.2. FluorIA procedure. The first step of the FluorIA procedure is to prepare RPA
plates (Figure 2.4 top left). Purified RPA, diluted to 0.2 µM with milli-Q water, is
dispensed by Multidrop Combi (ThermoScientific) to uniformly fill each well of a 384well, high-binding, “MaxiSorp”, black Plastic, flat bottom, opaque microtiter plate
(Thermo Fisher Scientific, #460518) to 75 µL volume. Centrifugation at 500 xg for a few
seconds prevents air bubble formation and evenly coats the well. Plates are then
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incubated on an orbital shaker for 1 hour at room temperature, then excess protein
solution is decanted by flicking plates upside down several times and striking repeatedly
against a pad of paper toweling to remove residual liquid. Unbound RPA is removed by
two washes, 85 µL per well, using wash buffer (1X PBS with 0.2% Tween-20) with
elimination of residual liquid after each washing step as described above. Freezingblocking buffer (5% milk in 1X PBS with 30% glycerol) is then dispensed at 85 µL per
well and plates briefly centrifuged. Following a 10 min room temperature incubation on
an orbital shaker, each plate is sealed with an aluminum adhesive sheet (Thermo
Scientific, Cat. # AB-0626) and stored in the -20 ºC freezer until use. Typically, we can
make 60 to 80 RPA plates per day.
On a screening day, the desired number of RPA plates are thawed for 1 hour at room
temperature. Then the aluminum seal is removed, and the freezing-blocking buffer
decanted. The plates are washed once and decanted. Two protein mixtures are prepared
on the day of the screen: mixture-A is 1.33 µM RAD52(1-303) with 2.67 µM EGFPRAD52 in 1xPBS-5% milk, and mixture-B is 2.67 µM EGFP-RAD52 alone in 1xPBS5% milk. In the optimized protocol 75 µL of each protein mixture is used per well.
Mixture-A is dispensed into one column per plate to serve as a positive control (known
inhibitor, Figure 2.4, column 21) while mixture-B is dispensed into all wells that receive
a test compound from the chemical library or buffer only control. A column is reserved
for 1xPBS-5%-milk as a buffer blank (Figure 2.4, column 22). At this point, the RPA
plates are ready to receive compounds from a chemical library. A Biomek F/X liquid
handler (Beckman Coulter LifeSciences) automated the transfer of test compounds from
a chemical library source plate into the wells of a RPA plate. After test compound
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addition, RPA plates are centrifuged at 500 xg for a few seconds. The plates are covered
with aluminum foil and placed on an orbital shaker for 1 hour at room temperature. Then
three washes are performed to remove unbound chemicals and excess protein before the
relative fluorescence (RFU) is measured using a POLARstar OPTIMA plate reader
(BMG LABTECH) on emptied plates at an excitation/emission (for EGFP) of 485/520
nm at 2500 gain setting. Plates must be read decanted as reading them with liquid present
increased variation in the data.
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Figure 2.4 HTS FluorIA procedure diagram and representative data.
Columns 1-20 are the screen of a chemical library. Column 21 is inhibited
with RAD52(1-303) control and column 22 is buffer control. Column 21 is
the PC and column 22 is the NC in wquation 2. Well K18 is a hit.
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2.3.3. Strategy for screening libraries of compounds. For large library screening, a
single concentration is used (e.g. 100 μM). Plates are repeated to eliminate false hits.
Then triplicate repeats further verify hits. With this strategy, it is possible to screen up to
10,000 compounds per day with two workers.
2.3.4. Statistical analysis. A screening window coefficient (denoted Z-factor) is used to
assess the quality of the signal throughout screen optimization and application.
3SD of sample+3 SD of control

Z = 1 − |mean of sample−mean of control|

(1)

Here, the assay value in the absence of potential inhibitor is the “sample” while the
“control” is the value in the presence of the known competitive inhibitor RAD52(1-303).
In some early pilot assays EGFP was the control. If 1 > Z ≥ 0.5 then the separation band
between the sample and control is large enough and the assay is considered excellent.
Candidate SMI hits are identified as follows: On each screening plate, the average value
of a designated column containing no potential inhibitors and buffer only is a negative
control (NC). The average value of a column containing the known inhibitor RAD52(1303), is the positive control (PC). Then
Xhit = (NC −

NC−PC
2

) 100

(2)

A SMI is considered a hit if Xhit is 50% or lower (Figure 2.4, shown as light orange in
well K18). A value of 50% is used for this example because the RAD52:RPA PPI under
study probably involves two binding surfaces and a hit might bind to only half of the
uncharacterized surface. The hits are also three standard deviations below the NC.
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2.4. Results and discussion
Previously, we used an ELISA-based method that required antibodies and
chemiluminescence for detection to analyze the domains of RPA interaction on RAD52
and vice versa.[103]. This method worked well for biochemical type assays but is too
cumbersome, expensive, and uses far too many wash steps to be practical for HTS. The
FluorIA is a new approach that obviates the need for antibodies, thus avoiding problems of
non-specificity, and detects PPI simply with purified proteins with a minimal number of
steps and low cost. Here, purified RPA is directly bound to a black, high-binding microtiter
plate and the PPI detected with RAD52 tagged with EGFP (Figure 2.1C and Figure 2.3).
An increased relative fluorescent unit (RFU) is detected when EGFP-RAD52 is added to
RPA (Figure 2.5). A similar response is not detected with the EGFP tag alone indicating
the interaction is between RPA and RAD52 not between RPA and the EGFP tag. Z-factor
analysis with EGFP tag as a control helped us select minimal protein levels that gave an
optimal response (Figure 2.5). The best Z-factor value along with lower variation in
replicates was obtained for 20 pmol of EGFP-RAD52 per well added to 10 pmol of RPA.
Despite higher signal value with 40 pmol EGFP-RAD52, we use 20 pmol concentration
for HTS as it gives a consistently good Z-score in repeats and meets the goal of lowering
the cost of reagents. We tested pilot assays with 25 μL/well or 75 μL/ well reaction (data
not shown). A 75 µL volume gives the best signal as it filled the small 384-well without
overflowing and allowed RPA to bind the flat bottom as well as the walls of the well for
increased signal. As optimization progressed, we increased the amount of RPA to 15 pmol
to ensure sufficient RPA per well after multiple washing and handling procedures.
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Excellent Z-factors greater than 0.5 are obtained in the FluorIA mainly due to the low
standard deviation of the screen and large difference between PC and NC.
Temperature is another factor to consider. To see the effect of temperature, two plates
were incubated at 22 °C and 28 °C individually (Figure 2.6). The results suggest that it is
best to perform the screen at room temperature and to watch the thermostat. Higher
temperature fluctuations probably result in detachment of the bound RPA from the wells
resulting in lower signal. Therefore, the FluorIA is conveniently conducted at room
temperature.
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Figure 2.5 Optimization of protein levels per well. Z-factors were 0.39, 0.73 and 0.66 for
10, 20, and 40 pmol respectively.
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Figure 2.6 The effect of temperature on FluorIA. The reaction
was done at 22 ºC and 28 ºC.
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Further development of the assay required the use of a robust known inhibitor for the
statistical analysis of each plate and hit identification. Previous work by our group shows
that RAD52:RPA electrostatic interaction can be disrupted by increased salt
concentration.[103] Therefore, we diluted the EGFP-RAD52 with a range of 0-1 M KCl
before adding it to the RPA plate. Consistent with our previous findings, inhibition was
evident by a progressive decrease in fluorescence signal with increased salt concentration
(Figure 2.7A). However, it was evident that a much larger salt concentration was required
to achieve the desired baseline inhibition. The possibility of salt interfering with the
chemical libraries motivated us to search for an alternative inhibitor.
Previously, we demonstrated that the primary interaction sites for RPA on RAD52 are
within residues 193-303 [103]. Also RAD52(1-303), which has intact RPA binding
domains but is missing the remaining 115 residues at the C-terminus, exhibits a slightly
higher RPA binding activity compared to full length RAD52 [103]. Interestingly, Plate and
coworkers reported an enhanced repair activity for a yeast Rad52(1-307) construct
compared to full-length Rad52 [78]. Accordingly, RAD52(1-303) inhibits the FluorIA by
competing with EGFP-RAD52 for RPA binding. In a pilot screen, 20 pmol of EGFPRAD52 was incubated with increasing concentrations of RAD52(1-303) in the RPA plate
(Figure 2.7B). At a molar ratio of 1:1, 50% inhibition is observed and with increased
concentration of RAD52(1-303), baseline inhibition is achieved. Therefore, 100 pmol of
RAD52(1-303) is used as a known inhibitor (positive control) in the FluorIA.
At this juncture, it was necessary to assess the resilience of the FluorIA readout signal
with the added challenges of a HTS. Typically, compounds in chemical libraries are
dissolved in 100% DMSO and that could be detrimental to the integrity of purified proteins,
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the main components of the FluorIA. We plan to limit the final concentration of DMSO to
no more than 5% per reaction well in HTS. To see any effects, different amounts of DMSO
were added with EGFP-RAD52 before incubating in the RPA plates (Figure 2.8).
Fortunately, up to 5% DMSO has no significant effect on the FluorIA signal.
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Figure 2.7 Known inhibitor. Finding suitable competitive
inhibitors to serve as control (A) KCl or (B) RAD52(1-303).
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Figure 2.8 Testing the effect of DMSO. DMSO was added up to 5% in the
FluorIA reaction.
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The parameters defined above provide the essentials for an HTS assay, namely,
sensitivity, reliability, and homogeneity. Subsequent work creates a successful process for
screening large libraries with minimum time and maximum cost efficiency. Assay steps
need to be minimized and automated for simplicity and speed. The storage of assay plates
over various times and to optimize proper storage conditions was addressed. Once the
storage condition in 30% glycerol at the blocking step was found to be optimal, three
different RPA plates were tested after freezing overnight to assess plate-to-plate variability
(Figure 2.9A). As no difference was detected, we conducted the freezing test for up to two
weeks and freezing did not lead to change in signal output (Figure 2.9B). Thus, making the
RPA plates ahead of time and freezing them provides a convenient stopping place in the
FluorIA protocol. Also, having the RPA incubation, washing, and blocking steps done
ahead significantly mitigates the number of steps to be done on the day of HTS, reduces
the risk of costly errors and allows for screening of several thousand chemicals a day. The
case is not the same with EGFP-RAD52. The EGFP signal diminishes with time stored
(Figure 2.9C). EGFP-RAD52 must be freshly purified the week of the screen. On a HTS
day, it is critical to perform a test plate of all proteins and buffers to test activity and Zfactor before committing to a long day of screening.
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Figure 2.9 Reagent shelf life. (A) RPA plate variation with three different RPA
assay plates prepared, sealed and frozen overnight. (B) Effect of short term freezing
on RPA plates. (C) Effect of freezing on purified EGFP-RAD52 signal. For part C,
nonbinding plates and gain setting of 1000 was used.
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The final optimized parameter is the buffer system. For most of the pilot optimization
screens, an EDTA-containing buffer system was used. By exploring other buffer systems
we found that 1x PBS gives a larger change between positive and negative controls
contributing to the statistical quality of the assay (Figure 2.10).
PPIs are important in biological processes as well as pathology. Here we demonstrate
how the simple FluorIA protocol can be used to find SMIs that disrupt the RAD52:RPA
interaction. Future HTS of SMI libraries will follow the full FluorIA optimization
described here. The well-coordinated flow of the FluorIA and analysis makes it possible
to screen up to 10,000 compounds per day. FluorIA is applicable to PPI where the
purified protein maintains activity. FluorIA is not restricted to screening SMIs and is
suitable to test aptamers as well.
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Figure 2.10 Optimal buffer choice. Testing EDTA and 1x PBS
buffers in FluorIA.
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2.5. Conclusion
PPI take central importance in biological processes and their pathological changes.
Early developments of HTS were based on targets other than PPI. We now realize that
modulating PPI with small molecule is not only possible but advantageous in the quest of
targeted therapeutics.
We developed FluorIA to find SMIs that can disrupt RAD52:RPA interaction. Following
full optimization, we were able to do an unbiased screen of three large libraries of
potential SMIs. The flow of the HTS and analysis was well coordinated, and it was
possible to screen up to 10, 000 compounds per a screen day.
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Chapter 3
Characterizing the RAD52:RPA complex
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3.1. Abstract
RAD52 interaction with RPA constitutes a crucial step in its known and newly
emerging roles in DNA damage repair. RPA’s main function in the cell is to protect
ssDNA strands and relax DNA secondary structures during the process of normal DNA
replication or repair. RAD52 plays a role in repair processes such as HRR, SSA, or
break-induced repair processes, RAD52 requires direct interaction with the RPA
occupying the ssDNA at the damage site for activity. Recently, there is an increased
appreciation for RAD52’s role in the maintenance of tumorigenesis. The molecular and
dynamic details of RAD52:RPA interaction are of great interest with increasing efforts to
target RAD52 DNA repair activity to kill tumor cells. Here we use the FluorIA we
developed along with kinetic and thermodynamic measurements to investigate the
RAD52:RPA interacting. The interaction of RPA with RAD52 has dissociation constant
of 0.1 μM and the interaction appears strong enough to be physiologically relevant and
has the potential to be a therapeutic target.
3.2. Introduction
HRR is one of five major DNA repair pathways that make it possible for cells to
combat DNA lesions encountered during the course of replication [104]. HRR is a
specialized and accurate repair for DNA DSBs, a type of DNA damage that is of a
particular significance in cancer [105]. Not surprisingly, PPIs in this repair pathway are
of central importance in tumorigenesis development and potential candidates in targeted
therapy [106, 107].
RPA is a heterotrimer composed of three subunits and binds ssDNA intermediates of
DNA metabolism and repair processes [77, 108]. The dynamic nature of this binding
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stretches beyond protection into specific and essential interaction with protein partners to
ensure the efficiency of these processes [109]. RAD52 is an important protein partners
that functions in HRR, SSA, BIR, RNA-templated DSBs repair [57, 66, 75]. With RPA
being an early responder, when RAD52 seek to repair damaged DNA, RPA had already
proceeded to the site making this PPI crucial in initiating the repair processes. RPA
interaction is reported to either dictate or stimulate RAD52 repair activity. Plate and coworkers demonstrated that there is a requirement for direct interaction with RPA for
Rad52 to carry out its role in HR repair [78]. Moreover, in the newly characterized role
for RAD52 in RNA-templated DSBs repair, the addition of RPA to the reaction clearly
stimulated the repair activity [72].
RAD52 and RPA proteins received great interest from researchers due to their
significant roles in normal and pathological processes. Flexible linkers connecting the
three subunits of RPA hindered efforts for a full structural view of the protein [110-116],
while RAD52 was revealed as a ring structure using electron microscopy and X-ray
crystallography [117-120]. The RAD52 ring was predicted by Singleton to provide a
positively charged groove as a binding pocket for ssDNA [120]. This structural
knowledge along with emerging understanding of RAD52 role in tumorigenesis,
motivated the search for therapeutic agents that can disrupt the RAD52 ring to target its
activity [62, 74]. Our past data showed that conformational changes offered by RPA
interaction dictate the activity of RAD52 in DNA repair. Namely, we found that in the
absence of RPA, RAD52 existed in rings and aggregates of rings. However, monomer
RAD52 purified in a stable complex with RPA-ssDNA. Additionally, we found that RPA
alone was capable of promoting the breakage of the RAD52 ring structure. These
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findings motivated our interest in the RAD52 monomers as the potential active form in
DNA repair [79, 103].
Here, we aim to characterize the RAD52:RPA complex and validate its candidacy for
targeted therapeutics. FluorIA, was used to delineate the RPA-binding domains on
RAD52. Using the same method, the RAD52 interaction surface on RPA, based on
previously reported NMR data, was investigated [121]. SPR was then utilized to study
the affinity of RPA interaction with full-length and truncated mutants of RAD52. Finally,
ITC analysis was used to validate our SPR findings for the full-length proteins.
3.3. Materials and methods
3.3.1. Proteins purification.
RPA purification was done as described in Chapter 2. To make the ssDNA:RPA
complex, RPA was mixed with an excess molar concentration of a 25-mer
oligonucleotide (GCTAGCTCAATTCATCGACAAACCTT) (1:1.1 ratio) that was
synthesized and reconstituted as described by Deng and coworkers [79]. The complex
was incubated on ice for one hour before purification using size exclusion column (see
above) with 300 mM KCl in HI-0 buffer described in Chapter 2. Fractions containing the
complex were selected guided by the 260/280 ratio read by NanoDrop1000 and purity of
the sample as judged by SDS-PAGE (Figure 3.1A).
The 6xHis-tagged RPA was expressed using the pET-Duet system. The plasmids
were made by GenScript with codons optimized for E.coli. RPA70 was cloned into
multiple cloning site 2 (MCS2) of pCOLA Duet-1 with kanamycin resistance. HisRPA14 and RPA32 were cloned into MCS1 and MCS2, respectively, in pACYC Duet-1
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plasmid with chloramphenicol resistance. These were transformed into BL21(DE3) E.coli
with chloramphenicol and kanamycin selection. The expression procedure was as
described for RPA in Chapter 2. A 5 g cell pelleted His-tagged RPA was resuspended in
25 mL of buffer A with 250 μL of PIC and lysed. Clarified and filtered lysate was then
loaded onto a HisTrap FF column (5 mL, GE Life Sciences). The protein eluted with a 25
CV gradient to 1 M imidazole in buffer A. The purity of the protein fractions were
examined by 10% SDS-PAGE (Figure 3.1B).
6xHis tagged RPA32(172-270), also known as the winged-helix-loop-helix region
(wHLH) (MW 9.4kDa), a generous gift from Dr. Marc Wold and was transformed into
Rosetta2(DE3) with chloramphenicol and kanamycin selection. Protein expression was as
described for RPA in Chapter 2. For purification, a RPA32(172-270) pellet was thawed
and resuspended in buffer D [10 mM NaPO4 pH 7.5, 150 mM NaCl, 10 mM imidazole,
and 2 mM β-ME] with 250 μL of PIC and lysed. Clarified lysate was filtered through a
0.45 μM filter then loaded onto a His Trap FF column (1 mL, GE Life Sciences). The
protein eluted with a 25 CV gradient to 1 M imidazole in buffer E. Pooled fractions were
diluted with 4 volumes of buffer F [20 mM NaPO4, pH 7.5, 50 mM NaCl, 2 mM βmercaptoethanol (β-ME), 0.5 mM EDTA] and polished using a monoQ anion exchange
column (1 mL, GE Life Sciences # 17-5166-01). The protein was eluted in a 25 CV
gradient of 0-100% 1 M KCl in buffer F. Since 6xHis-RPA32(172-270) has no
tryptophan, a UV absorbance at 210 nanometers was necessary for detection of protein
fractions. Fractions were also examined by 12% SDS-PAGE (Figure 3.1C). The
bicinchoninic acid assay (BCA assay) was used to measure protein concentration.
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The His-tag was removed from a portion of the purified wHLH by thrombin digestion
(10 U/mg tagged protein) to use it in SPR as an analyte over RAD52-bound to NTA chip.
Thrombin, loose His tags, and still-tagged protein were removed from the digestion
mixture by adding benzamidine resin (removes thrombin) and nickel resin (removes His).
Tagged and detagged wHLH were examined by 12% SDS-PAGE (Figure 3.1C).
RAD52(1-418), RAD52(1-303), and RAD52(1-212) all in in pET28, were
transformed into Rosetta2(DE3) E.coli with chloramphenicol and kanamycin selection.
RAD52 (168-306) and EGFP-RAD52(1-212) in pET28a (GenScript) were transformation
in BL21(DE3) E.coli with kanamycin selection. Expression and purification for all these
RAD52 constructs was done in the same manner described for RAD52(1-303) in Chapter
2. Purification of, RAD52 (168-306) and EGFP-RAD52(1-212) expression and
purification included an additional size exclusion (Superdex 200, HiLoad 16/60, GE Life
Sciences) purification step preceded by an overnight dialysis into a high-salt buffer (20
mM HEPES pH 7.5, 400 mM NaCl, 100 mM KCl, 1 mM EDTA, 2 mM β-ME, and 10%
glycerol). RAD52 (168-306) sequence contains no tryptophan so a UV absorbance at 210
nm was necessary for detection of protein fractions during purification. Fractions were
examined by 10% SDS-PAGE with Coomassie stain (Figure 3.2). The RAD52(257-274)
peptide was purchased (GenScript). Peptides was diluted to 10 mM in nuclease-free
water and stored frozen at -20 °C
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Figure 3.1 Purified proteins in SDS PAGE gels. (A) Fractions of
ssDNA: RPA, (B) 6xHis- tagged on RPA14 subunit next to untagged RPA14,
(C) RPA32(172-270) with or without 6xHis tag
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Figure 3.2 SDS PAGE gels shown His-RAD52(168-306).
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3.3.2 Isothermal titration calorimetry procedure and sample preparation. ITC
titrations were performed on an iTC200 (Malvern Instruments Inc. Northampton, MA). A
total of 15 injections of RPA with concentration 150-300 µM were performed into a 0.2
mL reaction cell containing a solution of RAD52 with concentration about ten times
smaller than the titrant. The total injection volume was 37 µL with individual injection of
2 or 3 µL. All experiments were carried out at room temperature and mixing rate 1000
rpm. Reaction heats were measured by integration of the area of the injection curve,
corrected for the dilution heat of the titrant, and normalized by the moles of titrant added.
Experiments with a low range of RPA concentrations (150-170 µM) were performed to
measure the heat of reaction directly in initial steps of the titration. The average of 4-5
injections at concentrations less than saturation provides the reaction enthalpy, ΔHITC.
The resultant thermograms were analyzed using single set of binding sites model of the
MicroCal LLC software based on the Levenberg-Marquardt non-linear least square curve
fitting algorithm to provide binding affinity, binding stoichiometry and enthalpy of
binding (ΔH°). The binding free energy (ΔGº) and the entropic contribution to binding
were then calculated using standard thermodynamic relationships.
Purified RPA and RAD52 were first concentrated separately using spin concentrators
(30,000 and 3,000 MWCO respectively). RPA and RAD52 were then dialyzed separately
against 1x PBS buffer with 1 mM EDTA and 2 mM βME overnight followed by a second
round the next day for a minimum of three hours. Concentrations of the proteins were
checked before and after dialysis using a NanoDrop1000 applying ɛ280=87.2 M-1cm-1 for
RPA and ɛ280= 20.4 M-1cm-1 for RAD52.

68

3.3.5. Surface plasmon resonance analysis. OpenSPR instrument (Nicoya
Lifesciences,) as well as Biacore 3000 (Biacore AB, Uppsala, Sweden) were used.
OpenSPR utilizes gold nanoparticles instead of traditional gold SPR films for the sensor
chip. Also the OpenSPR instrument uses LSPR that differs from traditional SPR in that it
employs readings of absorption of the sensor substrate chip.
For the OpenSPR analyses, sensor chips (SEN-Au-100-12-NTA) was installed and
Nickel labeled according to manufacturer’s recommendations. Based on experimental
pilot tests, 25-50 μg/mL of the His-tagged ligand could be bound on a chip. When the
ligand was a RAD52 construct, we used the HBS-PE running buffer [10 mM HEPES pH
7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% Tween20] at a higher salt concentration
of (500 mM NaCl) to ensure best binding and activity. To analyze multiple analyte
concentrations, multiple two or three-fold dilutions were made typically: 900, 300, 100,
33, and 11 nM along with a zero (HBS-PE buffer only) condition. HBS-PE buffer at 150
mM NaCl buffer was used as the running buffer in the system throughout the analyte
binding and regeneration processes. The salt concentration of 150 mM for ligand-analyte
binding was based on our previous work in making the RAD52:RPA complex [79].
Resulting data were processed using TraceDrawer software provided by Nicoya. Each
experiment was repeated several times and repeats with the best fit Chi2 value were
selected for average, standard deviation and variance calculations.
Interaction analyses of full-length RPA and RAD52 were also done using a Biacore.
For this kinetic analysis, amine coupling with a CM5 sensor chip was performed. RAD52
was chosen to be the ligand to bind the carboxymethyl groups containing CM5 chip
while RPA was flowed over as the analyte.
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A 20 mM MES buffer (pH 5.5) was chosen for immobilization of ligand while 1x
PBS containing 0.005% Tween was used for running the analyte. Then 10 mM
glycine/NaOH (pH 10) was used for regeneration. The CM5 used chip used
preconditioned with two short pulses of 50 mM NaOH, 100 mM HCl and 0.5% SDS. To
prepare for ligand binding, individual ligand flow channels were activated with a mixture
of 1-ethyl-3-[3-dimethylaminopropyl carbodiimide hydrochloride) (0.2 M) and sulfo-Nhydroxysuccinimide (0.05 M). RAD52 (5-20 μg/mL) was prepared for immobilization in
20 mM MES buffer (pH 5.5). Ethanolamine-HCl was used to block the remaining excess
ester groups. The immobilization process resulted in the coupling of RAD52 at a density
of 1200 RUs (an arbitrary response unit which corresponds to 1 pg/mm2).
Analyte buffer replaced the immobilization buffer and a series of RPA dilutions were
prepared for programed injections over the chip. Activation, regeneration, and blocking
solutions were provided by BIAcore. All data were collected at 25 ºC and evaluated using
BIAevaluation software (version 3.0). Out of the several experimental repeats, two are
selected for their lowest Chi2 values of 2.1 and 6.6.
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3.4. Results and discussion
3.4.1. Analysis of reported RPA-binding domains on RAD52. Min Park used GSTpull down studies to identify that the RAD52 region which mediates RPA interaction was
located within the basic region composed of residues 221 to 280 [122]. Plate and
colleagues used yeast Rad52 in a series of mutational and biochemical studies to identify
that RPA is able to interact with Rad52(169-260) (yeast Rad52 numbering) [78]. None of
the studies mentioned above or others can exclude the possibility for the existence of
additional RPA-interaction domains on RAD52.
Previously, our group estimated that the interaction site for RPA is within the RAD52
region encompassing residues 193-303 by ELISA analysis using different RAD52
constructs and RPA domains [103]. Interestingly, RAD52(1-303) and RAD52(218-418)
showed slightly higher binding activity than full-length RAD52 [103]. These results lead
our curiosity to find out if this binding activity is due to an additional RPA binding site in
the N-terminus besides the known binding domain in the C-terminus (residues 221 to
280).
We used FluorIA to analyze the competitive binding capacity of RAD52(1-303) and
RAD52(1-212) versus EGFP-RAD52. 20 pmol of full length EGFP-RAD52 was mixed
with 100 pmol of either RAD52(1-303) or RAD52(1-212) to incubate with RPA. The
results shown in Figure 3.3 suggest that the RAD52(1-212) can compete for RPA binding
with full length EGFP-RAD52 albeit less strongly than observed with RAD52(1-303). To
explore this further, we tested direct interaction of RPA with EGFP-RAD52(1-212) and
the results depicted in Figure 3.4 suggest binding activity to RPA.
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Figure 3.3 Competitive binding in FluorIA. A) SDS-PAGE gel shown full-length RAD52(1-418) to
the left of the molecular weight marker, RAD52(1-303), and RAD52(1-212). B) FluorIA reaction in which
20 pmol of EGFP tagged full-length RAD52 is incubated with RPA alone or with a 100 pmol of unlabeled
RAD52(1-303) or (1-212) to compete with EGFP-RAD52 for RPA binding. Reduction in RFU signal
signifies more binding activity of the unlabeled RAD52 construct.
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Figure 3.4 RAD52(1-212) binding to RPA. A) SDS-PAGE gel shown left to right, EGFP-tag, Nterminal EGFP-tagged full-length RAD52(1-418), and N-terminal EGFP-tagged RAD52(1-212). B)
FluorIA reaction in which 20 pmol of EGFP tagged full-length RAD52, EGFPRAD52(1-212), or EGFP
tag are incubated with RPA. Decreasing RFU signal signifies less binding activity as guided by baseline
signal of EGFP tag alone with RPA.
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Further work is needed to dissect the role of each of these two RPA-binding domains
in the DNA “hand-off” mechanism during the repair process but most importantly, this
information is vital when a therapeutic inhibitor of RAD52 interaction with RPA is
selected.
3.4.2. Surface plasmon resonance. The outcome of our FluorIA analysis of
RAD52:RPA binding activity motivated an investigation to determine the kinetic
parameters of these interactions. SPR analysis was conducted using the different RAD52
constructs and the results are summarized in Table 3.1. A representative SPR curves for
the different complexes each showing the different analyte concentrations are presented
in figure 3.4. The primary function of RPA is to bind ssDNA and this complex provides
further stability to the RAD52 interaction [79, 115, 123]. SPR analysis confirmed that the
RPA:ssDNA complex had stronger affinity with RAD52 than RPA alone. RPA
interaction with RAD52(1-303) was similar to full-length RAD52. More precise
experimental measurements of EGFP-RAD52(213-418) show similar interaction affinity
to full-length RAD52 and RAD52(1-303) with RPA. RAD52(1-212) and RAD52(168306) interactions with RPA also show similar binding affinities. The interaction of these
construct is, after all, electrostatic and thus show similar values. The data here disprove
previously-speculated negative regulation role for the RAD52 C-terminus.
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Table 3.1. Binding affinities of different RAD52 and RPA constructs.
Complexa

KD (M)b

wtRPA:wtRAD52

1.9*10-7 (2.0*10-8 S)

(ssDNA:RPA):wtRAD52

1.1*10-7 (1.5*10-8 V)

wtRAD52:RPA(1-303)

1.7*10-7 (9.2*10-8 V)

wtRAD52:RPA(1-212)

4.8*10-7 (1.7*10-7 S)

RPA:EGFP-RAD52(213-418)

2.9*10-7 (1.1*10-7 V)

RPA:RAD52(168-306)

3.2*10-7 (1.2*10-7 S)

RAD52(257-274): RPA

7.3*10-6 (7.7*10-13 V)

RAD52(257-274):RPA32(172-270)

4.6*10-6 (1.6*10-7 V)

RPA32(172-270)RAD52(1-303)

1.2*10-9 (3.9*10-19 V)

a

For the complexes, the protein on the left is the analyte and the protein on the right is the ligand
and attached to the chip via His tag.
b

The parentheses on the in the right-hand columns are the errors estimated from the standard
deviation (S) or as variation (V) if only two trials were done.
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RPA:RAD52

- 11 nM
- 33 nM
- 100 nM
- 300 nM
- 900 nM

(ssDNA:RPA):RAD52

- 11 nM
- 33 nM
- 100 nM
- 300 nM
- 900 nM

RPA:RAD52(1-212)

- 100 nM
- 300 nM
- 900 nM

RPA:RAD52(1-212)

RPA:EGFP-RAD52(213-418)

RAD52(257-274):RPA

RPA32(172-270): RAD52(1-303)

- 100 nM
- 300 nM
- 900 nM

- 11 nM
- 33 nM
- 100 nM
- 300 nM
- 900 nM

- 11 nM
- 33 nM
- 100 nM
- 300 nM
- 900 nM

- 11 nM
- 33 nM
- 100 nM
- 300 nM
- 900 nM
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Figure3.5 Representative SPR curves. Legend on the right shows different analyte
concentrations flown over ligand and regenerating in between. Complex names are on the
top left corner with the analyte shown on the left side of the colon while the ligand is on the
right hand.
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It was based on HR activity analyses of different RAD52 truncations, that most of the
C-terminal half was excluded to obtain a crystal structure with a good diffraction quality
[119]. To explore this further, we designed a new His-tagged RAD52(168-306) construct,
which excluded the C-terminus beyond the RPA binding domain and included the linear
sequence arm known to facilitate oligomerization [119, 124]. The binding affinity of this
construct of RPA is the same as of RAD52(1-303) and RAD52 (1-212). The results
further support the idea that a portion of the N-terminal region of RAD52 is involved in
binding of RPA. Additionally, comparing the KD values of RPA with RAD52(168-306)
to that with EGFP-RAD52(213-418) in table 3.1, we observe that the interaction affinity
was not significantly reduced. This information suggests the absence of a domain of
RAD52 C-terminus that might be negatively regulating the PPI.
RPA(172-270) is a region which contains a wHLH structure required for DNA repair
and a site for PPIs [115]. RAD52 is among the interacting partners on this region and its
interaction affinity was of interest. As our data indicates that RAD52(1-303) contains the
entire RPA binding sites, interaction with RPA(172-270) yielded a strong binding affinity
1*10-9 M. This is interesting as affinity was lower when a full RPA trimer (1.9*10-7)
suggesting that the full-length is offering inhibitory regions that are of importance to the
dynamic of interaction. Early work by Bochkarev and colleagues in their work showing a
DNA-binding activity within the RPA32/14 complex, suggested that N- and/or Cterminus of RPA32 harbor domains that inhibit ssDNA binding. In later structural work
by the group, suggested that those RPA32 inhibitory domains are near the L45 loop
known for promoting ssDNA binding and might be affecting its mobility and reducing
affinity of interaction with DNA [110]. The strong affinity of interaction of RPA32 C-
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terminus with RAD52(1-303) we observed here suggests a regulatory mechanism for this
domain in supporting PPI and DNA interaction. Further work is needed to understand if
increase in affinity for RAD52 is an an accompanying event with reduced affinity for
ssDNA.
Interestingly, Mer and colleagues carried NMR analysis of RPA(172-270) with
RAD52(257-274) and found that the exchange between free and bound state of the
RAD52 peptide was fast on the time scale of chemical shifts, indicating a weak binding
[121]. The KD of two other protein partners, UNG and XPA, were reported in their study
to be 1 and 5 µM respectively and RAD52 peptide was speculated to be weaker. We
measured RPA(172-270) interaction with RAD52(257-274) and obtained a KD of 4.6*106

M) which is in excellent agreement with their reported KD values.
We explored the potential inhibitory effect of RAD52(257-274) peptide of

RAD52:RPA interaction when added as an SMI in FluorIA reaction (Chapter 2). No
inhibition was observed for up to 100 μM. This suggest that a binding affinity greater
than 7*10-6 is needed to inhibit the complex. Similar reactions were carried out with other
RAD52 peptides we designed (detailed in Appendix I) and no inhibition was observed in
singles or synergy. These results is probably attributed to weaker affinity as found with
RAD52(257-274) but it is also possible that the peptides probably do not assume a
structure that mimics the PPI.
The kinetics of RAD52:RPA interaction was also analyzed with a different SPR
instrument and method of coupling. Biacore 3000 was used as described, utilizing amine
coupling technique to immobilize RAD52 on the CM5 chip and conduct kinetic analysis
with RPA. Out of the several experimental repeats, two were selected for their lowest
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Chi2 values of 2.1 and 6.6. The average KD value was 7.8*10-7(±1.3*10-7 V). This KD
value obtained was close to that obtained from the OpenSPR system (1.9*10-7) despite
the different instruments and coupling methods employed for immobilization.
3.4.3. Isothermal titration calorimetry. The thermodynamic parameters for the
RAD52:RPA interaction were investigated using ITC. A high concentration of RPA
(150-300 μM) was titrated against about one-tenth concentration of wt.RAD52 to obtain
the binding isotherms of the reaction (Figure 3.6). Binding was confirmed in ITC but the
value we obtained was off by one order of magnitude probably due to experimental
conditions. We further calculated thermodynamic parameters using the exothermic ΔH
value (Table 3.2).
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Figure 3.6 ITC profiles for the titration of RAD52 with RPA. The top panel represents a
sequential injection of RPA into a solution of RAD52 and the bottom panel shows the
integrated heat data against molar ratio of [RPA] / [RAD52] after correction of heat of dilution.
Data points were fitted to one site model and the solid line represents the best fit data with
fixed N=0.5 and fixed ΔH=8.2 kcal/mol.
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Table 3.2 Thermodynamic parameters for RAD52:RPA interaction.

ITC experiments

K (M−1)

ΔGᵒ (kcal/mol)

TΔS (kcal/mol)

RPA on RAD52
(run #1)

1.6*105 (2.7*104)

-97.7

-89.50

RPA on RAD52
(run #2)

7.0 *105 (1.7*104)

-404.5

-396.3

Two ITC runs are selected (run 1 is shown in Figure 3.5). ΔGᵒ = -RT*In(K) equation was used
to calculate ΔGᵒ and this value was used to calculate TΔS according to the equation ΔG = ΔH –
TΔS and using the average ΔH= -8.188 Kcal/mol
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3.5. Conclusion
RAD52 interaction with RPA is a promising candidate therapeutic target. Inhibiting
RAD52 repair activity can deprive tumors of an important survival and maintenance
factor. RAD52 activity is guided and dictated by RPA which guards the ssDNA near the
damage site. It was imperative, therefore, to understand the nature of this PPI.
Given the formidable nature of both proteins to full structural analysis, we utilized
multiple techniques by which we moved from global understanding of binding activities
to detailed calculations of binding affinity and thermodynamic parameters. With this
information and close examination of available structural information, we developed a
new understanding for RPA-interacting domains on RAD52.
Number of important findings were presented here in characterizing RAD52
interaction with RPA. First, we confirmed previous supposition for the presence of an
additional RPA-binding domain within the RAD52 N-terminus. Second, our data here
disperse key aspects that will be of significant value to further investigate domains
involved in regulating the dynamic process of DSB repair. Our data disproves previouslyspeculated negative regulation role for the RAD52 C-terminus as including the rest of the
C-terminus did not reduce the affinity of interaction with RPA. Further, measurements of
the C-terminus wHLH region of RPA32 with RAD52(1303) yielded a strong interaction
affinity, which was reduces when full-trimer RPA was used. This indicates the presence
of a domain in the RPA trimer that weakens the interaction with RAD52. What is
interesting about our finding here is that the C-terminus of RPA32 containing the wHLH
region, was implicated in offering structural dynamics that reduces the affinity of
interaction with ssDNA. We have yet to understand whether the strong interacting
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affinity with RAD52 is an accompanying event that supports the hand-off mechanism in
repair.
Overall, the measured KD values makes RAD52:RPA interaction a viable target for
SMIs. The information here will facilitates tailoring the appropriate method to find a
fitting therapeutic agent that can target this RAD52:RPA with an appropriate affinity and
selectivity. Moreover, the map and affinity of RAD52 interaction with RPA will guide
potential pharmaceutical inhibitors or modulators of this interaction.
New information here includes regions in RAD52(1-212) are important for binding
RPA. Also, it is clear that there is a large electrostatic component to the formation of the
complex.
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Chapter 4
HTS analysis and identification of potential
RAD52 inhibitors

88

4.1 Abstract
RAD52 activity has been shown to support the establishment and maintenance of
tumors by addressing their most challenging DNA repair problems such as DSBs and
collapsed replication forks. In HRR-defective cancer cells, RAD52 becomes particularly
important in providing a backup repair pathway and therefore, holds a promising
therapeutic value through synthetic lethality. While there has been several published
SMIs for RAD52, we differ here in our approach by seeking to prevent RAD52 repair
activity by impairing its interaction with RPA, an abundantly present protein on ssDNA
at DNA damage sits. RPA meets RAD52 at every junction in the latter’s quest to reach
damaged DNA. Beyond this obligatory physical interaction, we and others have
demonstrated that RPA dictates RAD52 recruitment and function in repair. Through a
HTS using FluorIA, we identified SMIs that inhibited RAD52 interaction with RPA that
selectively kill HRR-defective cancer cells.
4.2. Introduction
DNA damage response and repair have always been at the center of common
cancer chemotherapeutic and radiotherapy treatments directed to overwhelm repair
machineries with mounting DNA lesions. Cancer cells often show dependence on unique
DNA repair pathways due to frequent mutations in repair-related genes or proteins and
their higher demand for repair to sustain their active division. The evolving avenues in
targeted cancer therapeutics are not far from these principles, but aspire to zero-in on
selected factors that are dispensable for normal cells thus sparing them from collateral
damage [125]. Coupling maladaptive mutations in cancer with pharmacological
inactivation of another target to induce selective cell death is called synthetic lethality
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[101]. This approach minimizes side effects that exhaust patients and has the potential to
lift the roadblocks for the treatment of aggressive subtypes of cancers for which there are
currently no effective therapies. High-grade serous ovarian and triple negative breast
cancers, for example, are among the most lethal subtypes characterized by poor
prognosis, high rate of reoccurrence and metastasis [23, 126]. Many patients with these
specific subtypes harbor somatic mutations in BRCA1 or BRCA2 contributing to the
development and progress in PARP inhibitors [49, 127, 128].
Poly (ADP-ribose) polymerase (PARP) enzymes catalyze polymerization of ADPribose moieties (PARsylation). Serial of PARsylation facilitate the repair of SSBs in
DNA. Inhibiting this catalytic activity impairs SSB repair and cause the formation of
DSBs [129]. The exacerbating amount of DSBs is purposefully induced by PARP
inhibitors to challenge cancer cells. This approach appears to be effective against cancers
that are defective in HRR [130]. Cross-reactivity among some PARP family members to
developed inhibitors has unfortunately caused side effects emerged [131]. Also,
resistance to PARP inhibitors is a problem, so there is a need for additional selective
treatments for HRR-defective cancers.
The specialty and high fidelity of HRR for DSBs make it a candidate pathway to look
for cancer targets as exemplified by the story of PARP inhibitors [8]. Importantly, cells
with defective BRCA2 or related proteins shows dependency on RAD52 protein to
maintain functional RAD51-mediated HRR repair activity of DSBs [100]. In fact, other
RAD52 repair activities such as SSA were reported to increase in BRCA-related defects
in HRR [69, 71]. These findings helped establish a body of research targeting RAD52
activity to induce selective killing of BRCA-deficient tumors [60, 62, 74].
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New findings about the role of RAD52 in tumorigenesis further qualifies it as an anticancer target [132]. RAD52, for example, is specifically recruited to in break-induced
repair (BIR) and the restart of collapsed replication forks [66]. Supporting role in the
establishment and maintenance of tumors, RAD52 expression was found to be associated
with increased risk for lung cancer and its upregulation was observed in hepatocarcinoma
[19, 133]. Beyond the scope of its synthetic lethal relationship with the BRCAs, RAD52
inactivation was demonstrated to augment the immune response and improve therapeutic
response [73].
Development of an effective modulator or inhibitor are usually guided by
comprehensive structural and biomolecular aspects of the target. For this reason, we
characterized RAD52 interaction with RPA by SPR, ITC, and FluorIA as described in
Chapter 3. The data obtained was based on previous work done by our group that
delineated domains of interactions using an ELISA-based assay [103], stoichiometry by
SEC-MALS [79], structural analyses by crystallography methods [115], and
posttranslational modifications by various experimental methods [134].
Here we elaborate on using the FluorIA procedure, described in chapter 1, to conduct
a high throughput screening for SMIs targeting RAD52:RPA interaction. Over 101,500
compounds were screened from three different libraries. Eleven candidate hits were
obtained, five of which showed the strongest inhibition as determined by their high EC50
values in vitro. Three out of the five are FDA approved and two of these are anti-cancer
drugs.
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4.3. Materials and methods
4.3.1. Chemical libraries screened and handling of compounds. The FluorIA
procedure described in Chapter 2 was used here to screen for SMIs from three large
libraries: 1) The 355-member SelleckChem Kinase Inhibitor Library, the 1200-member
Prestwick Chemical Library, and the 100,000-member ChemBridge library. Compounds
from each library had been stocked at 10 mM in 100% DMSO and stored at -80 ºC in 384
plates (Nunc, 267460) termed as “master plates”. Daughter plates are prepared from
master plates by a 1:5 or 1:50 dilution in 100% DMSO of each compound into new 384well clear, round-bottom plates and stored in -20 ºC.
The screen of the SelleckChem Kinase Inhibitor and the Prestwick were done in two
concentrations of the drugs: 10 and 100 μM each in duplicate. As we moved to screen the
large ChemBridge library, we carried out the screen at a single concentration of 100 μM.
Questionable readings were repeated either as single wells or a whole plate. It was
possible to screen up to 10,000 compounds in a screen day. At the end of all screens, we
selected eleven chemicals that met the statistical criteria for a hit as described in Chapter
2, method section. Each of these hits were further verified in triplicate at 10 and 100 µM
in a separate FluorIA screen.
4.3.2. Dose response analysis of hits. Each compound determined to be a hit was taken
through a secondary screening to confirm its response. Subsequently, as dose response
curve (DRC) was generated to analyze the half-maximal effective concentration (EC50)
value in vitro. A source plate is created by hand-pipetting compounds from master plates
thawed at room temperature starting at 10 mM and serially diluted in half down to 6.0
µM using 100% DMSO. From each dilution point, a 12 µL/well were hand-pipetted in
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quadruplicate in a clear, round bottom 384-well source plate. Then100% DMSO was
pipetted in the same manner in one column of the source plate. Working plates are then
prepared by first binding 15 pmol/well of freshly purified RPA in the same way described
in Chapter 2. The RPA plate, however, is not subjected to freezing and is washed and
blocked. Then FluorIA protocol is followed as described in Chapter 2. Using the Biomek,
4 uL of each compound or DMSO are transferred from the source plate into the working
plate. At this point each well contains the experimental or control reaction in a final
DMSO concentration of 5%. With the addition of 4 µL from each compound in to a 75
µL reaction mixture, the concentration of chemicals would be reduced approximately 20x
generating final concentration series that ranges from 500 µM to 0.3 μM. Based on the
results of these experiments, hits that showed a dose response were ordered. Candidate
SMIs were purchased and a 1D NMR analyses was carried out to verify their identities.
Using the molecular weight value, each compound was dissolved in 100% DMSO to
achieve a stock concentration of 10 mM. Stocks of compounds were aliquoted and stored
frozen at -20°C. For in vitro DRC experiments, 5 x 103 where the response is the average
RFU of a triplicate at each concentration point, T0 is the average RFU of a triplicate the
negative control, and T100 is average RFU of a triplicate the zero-inhibition condition.
4.3.3. Cancer cell lines. Two cancer cell lines were used: 1) HCC1937 cell line (a
generous gift from Dr. Simon Powell) is derived from mammary gland, primary ductal
carcinoma at early onset of a tumor. This triple negative patient carried germ line
mutation in BRCA1 resulting in COO-terminal truncation protein and loss of the second
BRCA1 allele. A BRCA1-restored and an empty vector lines were also obtained by
transfection of a vector containing full-length human BRCA1 cDNA or an empty vector,
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respectively. 2) PE01 cell line derived from an ovarian cancer patient, with BRCA2
mutation, ascites at her first relapse post cisplatin chemotherapeutic treatment was
provided Dr. Tadayoshi Bessho along with a BRCA2-proficient revertant cell line, C4-2.
The latter line is one of eight clones from cultured PE01with restored BRCA2 due to
secondary mutation in BRCA2 that cancelled the original mutation as described in Sakai
et al. [135].
4.3.4. Cell viability assay. Cells were seeded 5 x 103 cells per well in 96-well plates in a
90 µL volume per well one day before treatment with exception to the HCC1937
BRCA1-restored cell line which required a higher density of around 5 x 104 cells per well
due to consistently observed slow growth and division behavior. For treatment, master
plates were made from the stock aliquots of compounds described above making 1:2
serial dilution starting from 10 mM down to 0.02 µM in 100% DMSO. 1:10 dilution was
made from there in 100% DMSO followed by another 1:10 dilution in cell culture media.
Finally, 10 µL of this compound solution is transferred onto the 90 µL of cells bringing
the final DMSO to 1%. Cells in 96-well plates were incubated with increasing
concentrations, adjusted to the level of sensitivity of the cells to the compound, or vehicle
control (1% DMSO) for 72 hours. For HCC1937 BRCA1-restord cell line, treatments
duration was extended to 96 hours accounting for the observed slow division and to allow
for enough doubling events while in treatment. Each treatment plate contained nine 1:2
dilution points of a drug in six replicates each: P1 (0–10 μM), P2 or P3 (0–2.5 μM). Cell
viability was determined using PrestoBlue reagent (Life Technologies, # A13261).
Fluorescent measurements were taken using a Spectramax M5 plate reader (MDS). To
assess cells’ replication in the absence of compounds as a control, six wells on each plate

94

were treated with vehicle to be read in triplicate at the initial treatment day as time zero
(T0) and at 72-hour read as time 100 (T100). The PE01 and C-42 cells lines were treated
in the same manner but due to higher sensitivity, the top concentrations were lower: P1
(0–5 μM), P2 (0–5 μM), or P3 (0–1.25 μM).

4.4. Results and discussion
4.4.1. High throughput screen and hits. Libraries screened, and hits obtained from each
are summarized in Table 4.1. No hits were obtained from SelleckChem Kinase Inhibitor
Library as expected. There were three hits from the Prestwick library: P1, P2, and P3 and
they showed the strong inhibition of RAD52:RPA interaction compared to the rest of the
hits (Figure 4.1). Eight hits were obtained from the Chembridge library with C2 and C8
being the strongest inhibition of the RAD52:RPA PPI (Figure 4.2). Based on their strong
in vitro inhibition and their significance as FDA-approved drugs, the three Prestwick hits
were selected for further cell-based characterization.
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Table 4.1 Chemical libraries screened by FluorIA and hits obtained.

Chemical Library

Hits

SellekChem

none

Prestwick

P1, P2, P3

Chembridge

C1, C2, C3, C4, C5, C6, C7, C8

P signifies hits from the Prestwick library while C is for Chembrige library.
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Figure 4.1 Dose response curve and relative inhibition values of Prestwick hits. (A)
Prestwick drugs were added in the series of concentrations up to 500 µM as described in Materials and
methods employing the FluorIA. Relative inhibition values were calculated against EGFP tag or
RAD52(1-303) as controls. (B) Half-maximal effective concentration (EC50) for each drug was
calculated using SigmaPlot 13.0 software with minimum and maximum adjusted to zero and 100
respectfully. Experiments were repeated three times for each drug. P1 and P3 precipitated in solution
at high concentrations and data points were eliminated for clarity.
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Figure 4.2 Dose response curve and relative inhibition values of Chembridge hits (A)
Chembridge compounds were added in the series of concentrations up to 500 µM to FluorIA reaction
as described in Materials and methods. Relative inhibition values were calculated against EGFP tag or
RAD52(1-303) as controls. (B) EC50 for each drug was calculated using SigmaPlot 13.0 software with
minimum and maximum adjusted to zero and 100 respectfully. Experiments were repeated three times
for each drug.
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4.4.2 Inhibition of BRCA-deficient cancer cells’ viability following treatments with
P1, P2, and P3. BRCA1 and BRCA2 are the main pathway in mammalian cells to
mediate the formation of RAD51 presynaptic filaments and catalyze the repair of DSBs
by HRR [33, 97]. RAD52, through its interaction with RPA, composes an alternative
pathway for cells lacking functional BRCA [100]. Targeting RAD52 activity in BRCAdeficient cancer cells was shown to induce synthetic lethality making it a valuable cancer
target [58, 59].
As an initial cell-based assessment, we obtained cancer breast and ovarian cancer cell
lines with impaired BRCA1 or BRCA2 function and tested their viability with P1, P2,
and P3 treatments. We rationalized that if these P1, P2, and P3 can inhibit RAD52:RPA
interaction, BRCA-deficient cell lines will be sensitive to those drugs. For the BRCA1deficient HCC1937 triple negative cell line, the results are summarized in Figure 4.3.
Following 72 or 96-hour treatment with increasing concentrations of either compound P1
P2, or P3 (0–5 μM) the viability of each cell line was analyzed. The effect of P1
treatment on viability was difficult to determine with an unexpected spur in overall
growth behavior. Treatment with P2 reduced cell viability in a dose-dependent manner
for BRCA1-deficient parental line (not shown) as it did in the empty-vector control while
inserted BRCA1 plasmid supported survival. P3 treatment indicates an overall cytotoxic
effect which might have masked any potential difference. Interestingly, treatment with
lower doses of P2 or P3 showed noticeable spur of growth albeit less than that observed
with P1.
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Figure 4.3 BRCA1-defective cancer cell line survival assay. HCC1937 corrected (BRCA+/+),
empty vector (BRCA-/-), and parental (not shown here) were treated with increasing concentrations of
(A) P1, (B) P2 and (C) P3 and incubated for three days at 37 °C. Corrected line needed additional 24
hr. in treatment due to slower growth behavior. PrestoBlue reagent was used to assess the viabilities
of the treated cells as detailed in Material and methods, and the obtained results were normalized to
vehicle control.
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The BRCA2-deficient PE01 ovarian cell line and it BRCA2 restored mutant C4-1
displayed different patterns of sensitivity. PE01 was sensitive to all three drugs showing
an overall reduced cell viability in a dose-dependent manner and ~75% inhibition with as
low as 0.31µM of P2 or P3 treatment. With P1 treatment, 5 µM was needed to reach a
similar level of inhibition. The interpretation of treatments’ effect for any lower dosages
was masked by enhanced growth for all three drugs in both cell lines in similar way
observed with HCC1937 cell lines (Figure 4.4) (lower data point with this issue are
eliminated for clarity). The EC50 values were determined through curve fitting and are
summarized in Table 4.2.
Unlike the HCC1937 with inserted BRCA1 plasmid, C4-2, with restored BRCA2,
shows evident reduction in viability in a dose-dependent manner with all three drugs
despite better survival rate than PE01. PE01 was derived from a patient with ovarian
adenocarcinoma at stage III who was sensitive initially to cisplatin and AG14361 PARP
inhibitor. However, she acquired cisplatin resistance and PARP inhibition resistance upon
a secondary revertant point mutation in BRCA2 [135, 136].
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Figure 4.4 BRCA2-defective cancer cell line survival assay PE01 and C4-2 cell lines were treated
with increasing concentrations of (A) P1, (B) P2 and (C) P3 and incubated for three days at 37°C.
PrestoBlue reagent was used to assess the viabilities of the treated cells as detailed in Material and
methods, and the obtained results were normalized to vehicle control.
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Table 4.2 EC50 for P1, P2, and P3-treated PE01 and C4-2.

Cell line

P1

P2

P3

PEO1

2.9 (0.32)

0.11 (0.036)

0.15 (0.07)

C4-2

5.4 (0.62)

0.37 (0.12)

0.43 (0.29)

EC50values here are experimental replicates with technical triplicates.
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C4-2 was among several PE01 clones obtained after four weeks in culture where
BRCA2 was restored. Functional significance of this type of restoration is unclear
particularly with the heterogeneity in resistance observed among these clones. No reports
of administering the anti-cancer P2 or P3 drugs in that patient’s chemotherapeutic rounds
after acquiring this secondary BRCA2 mutation were found. This data here suggest a level
of sensitivity in C4-2 and might be of therapeutic value to explore whether RAD52:RPA
inhibition bolstered this sensitivity.
The observed inhibition of the viability for these artificial BRCA2 mutants suggest an
impact on alternative repair and survival pathway in the absence of BRCA2. In addition
to the finding of the screen with respect to inhibition of RAD52:RPA interaction, further
work is needed to validate whether RAD52 activity is specifically targeted here and
whether that explains the compromised survival observed in BRCA-deficient cell line.
Collectively, cell viability assays revealed higher potency for P2 and therefore, it was
selected for this analysis.
The viability tests above guided a general understanding of BRCA-deficient cell lines
sensitivities to these three hit drugs. However, the varying phenotype and heterogeneity
in response were inevitable features of cancer cell lines. To validate inhibition of
RAD52:RPA interaction as we found in FluorIA, it was is necessary to examine drugs’
effect on specialized RAD52 pathway.
RAD52 is a primary driver of SSA type of HR where a search for homology usually
carried by RAD51 is dispensable when DSBs take place within direct repeats. RPA
covers the ssDNA exonuclease products at the DSB site and through interaction with
RAD52 ends are re-joining concludes the repair process with inevitable deletion of
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flanking sequences between the direct repeats. Pretreatment of SA-GFP U2OS with P2
was done by Dr. Bessho prior to expression of I-SceI and analysis by flow cytometry.
Similar treatment was carried out using D-I03, a RAD52 inhibitor recently published by
Dr. Mazin’s group [63]. DSBs repair activity by SSA was scored by GFP+ cells and
blotted as a function of P2, D-I03, or vehicle treatment. As will be soon reported in a
manuscript for publication, with 5 nM, P2 lowered SSA activity by over 50%, which is
4000-fold less concentration than D-I03 to reach this effect. The data suggests that
RAD52 repair activity is part of the mechanism of action for P2 and can be of great value
to explain the varied sensitivity to this drug among cancer patients.
4.5. Conclusion
RAD52 repair activity is valuable for the progress of tumorigenesis and we have
demonstrated through multidisciplinary studies that its complex with RPA is a candidate
to target for the development of selective anti-cancer therapies. While development of a
new targeted cancer drugs is an ambitious goal that we strive for, investigating the
mechanism of action of existing anti-cancer drugs should be a concomitant effort. As we
are understanding more about the genetic background behind cancer, it is vital to revisit
the therapeutic drugs in use and delineate the molecular maps behind their sensitivities
and resistance. The outcome of such studies will be of great benefit to the clinical
assignment of candidate patients for such drugs, building on the goal of personalized
medicine in cancer therapeutics.
We identified eleven potential SMIs for RAD52 interaction with RPA to induce
synthetic lethality in BRCA-deficient tumors. Surprisingly, three of those hits were FDAapproved drugs, two of which are known for their anti-cancer activities. While the
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general mechanism of these two drugs are known, varied sensitivities to them in patients
is not completely understood. Our work here leads to molecular clues that may explain
that variation. We show selective targeting of P2 to RAD52 repair activity; however,
further work is needed to identify its selectivity to RAD52 proteins and ways to enhance
its inhibitory action.
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Chapter 5
Conclusion and future directions
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A common starting feature in malignancies is uncontrolled cell division. There are
molecular factors that enable such behavior and others that work to maintain it in the face
of all defense mechanisms our bodies had developed. DNA damage and repair are central
processes in cancer and candidate enabling and maintenance factors can be identified
within these pathways.
RAD52 is currently recognized to promote tumorigenesis because of its crucial roles
in a number of repair activities at DNA damage stress sites. RAD52 repair activity was
specifically explored in different cancers and affirmed to be parallel to maintenance of
cancer cells’ survival. Work by Cramer-Morales and colleagues showed that BCRABL1- mediated leukemia (BRCA1-deficient) relies on RAD52 to repair increased levels
due to enhanced ROS-induced damage [60]. Remarkably, their work also showed that
depletion of RAD52 suppressed both cancer stem and progenitor cells expansion and
increased their apoptosis. In support of their work, a recent RAD52-/- mice model not
only demonstrated resistance to squamous cell lung carcinoma, but also augmented the
activity of CD8+ T cells and NK effectors [73].
Our work focused on characterizing the candidacy of RAD52 interaction with RPA as
a cancer target and development of a high throughput assay to screen libraries of SMIs
for this interaction. Previous successes scored in targeting PPIs was attributed to
thorough, multidisciplinary characterization of protein targets. Targeting PPI to inhibit or
modulate their activity is becoming an attractive approach in various therapeutics due to
their observed altered behavior of interaction or expression in disease. Large PPI
interfaces had traditionally posed a challenge for the idea of being modulated by small
molecules. However, protein mutational studies demonstrated that only some residue
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areas or “hot spots” may provide the binding energy for the small molecules to bind and
exclude the targeted protein partner [85, 90]. Successful HTS screens, for example, have
been credited for the discoveries of most enzyme-targeted small molecules that were later
adapted for other protein targets. To name a few, NMR-based screens [91], differential
scanning fluorimetry (DSF) [92], and 3D molecular modeling to select candidates for
HTS [94].
While these were useful approaches, their applications is usually costly and requires
the presence of specific instruments that are not readily available for every researcher.
FluorIA (Chapter 2) has no demand for expensive instrumentation yet is a robust and
homogeneous assay. We were able to screen large libraries of molecules with efficacy in
time, cost, and output. On a low-scale, FluorIA was proved valuable use in detecting PPIs
using full-length or truncated mutant proteins. This was particularly useful in delineating
the domains of interactions and coordinating such data with available kinetic and
structural data to characterize RAD52 interaction with RPA (Chapter 3).
The libraries we screen yielded interesting potential SMIs in terms of identity and
structure (Chapter 4). We focused particular attention on the three FDA-approved drugs
hits. We characterized several BRCA1/2-deficient cancer cell lines’ survival with these
three hits treatment. Despite the challenges encountered with the heterogeneous behavior
of culturing cancer cell lines, we observed a general survival in the presence of
BRCA1/2. P2, being an anti-cancer drug was particularly interesting. The data we have
suggest that targeting RAD52 repair activity might be part of the mechanism of action for
P2 and can be of great value to explain the varied sensitivity to this drug among cancer
patients.
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Understanding the mechanism of action of existing anti-cancer drugs is equally
important as discovering new ones. Varied resistance and sensitivities to current therapies
has always been a challenge and delineating the molecular basis for this variation is
valuable in the quest for personalized cancer therapy. A great example for this was
demonstrated through vorinostat, a drug that showed significant success in reducing brain
metastases particular experienced by TNBC patients. The known mechanism-of-action
for vorinostat was its action as a histone-modifying agent [137]. Palmier and colleagues
demonstrated that decreased RAD52 expression augments vorinostat’s action by
promoting accumulation of unrepaired DSBs [138].
In clinical literature, P2 was reported to have the highest anti-cancer activity in
patients with BRCAness. There is a generally accepted mechanism of action for P2 that
does not address the varied sensitivity in BRCA-deficient tumors. Interestingly, there are
reported efforts to sensitize other non BRCA-deficient subtypes of breast cancers to P2
through targeting other DNA repair pathways. Accordingly, we anticipate that our
research will explain a new mechanism-of-action in which the success in P2 use with
BRCA-deficient breast or ovarian cancer patients might be attributed to the synthetic
lethality achieved by inhibition of RAD52 activity.
We will further characterize the eleven potential SMIs, particularly the strongest five,
by in vivo and in vitro experiments. Additional future work will include determining the
protein partner binding (RPA or RAD52) and the affinity of binding. We will also use
protein painting method and crystallography to further understanding binding pockets and
interacting residues [139]. With the knowledge we have of interacting domains of RPA
on RAD52, we plan to link the best of the SMI with each other or with other published
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SMIs which inhibit binding directly to ssDNA to achieve more specific binding and
selective targeting of RAD52.
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Appendix I.
RAD52 peptides design and analysis in the
FluorIA
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Introduction
The RPA32(172-270) wHLH region is known to be a site for PPI. The interaction
interfaces of UNG2, XPA, and RAD52 with this region has been examined by NMR
analyses. Residues of UNG2 protein involved in long-range Nuclear Overhauser
enhancements (NOEs) were aligned with corresponding residues of XPA and RAD52
[121]. We used the RAD52(257-274) from this group plus an additional eleven RAD52
peptides based on analyses of the RAD52(1-212) crystal structure in the FluorIA assay to
further investigate the overall RAD52:RPA interaction domains. The rational for peptides
was that this is a route frequently used to find PPI inhibitors.
Method
RAD52 peptides. Eleven RAD52 peptides were designed and purchased (China peptide)
(Table A1.1, peptides 1-11). The full RAD52(257-274) peptide was obtained as well
(GenScript) (Table A1.1, peptide 12). A stock was made at of RAD52(257-274) at10 mM
using nuclease-free water and stored frozen at -20 °C. All other peptides were peptides
were diluted to 10 mM using DMSO and stored frozen at -20 °C.
Two peptides (260-RQKQQQFR-269 and 253-ATHQRKLRQK-262) were generated
from NMR analysis where UNG2 residues involved in intermolecular NOE signals were
assigned, and the corresponding alignments with RAD52(257-274) were determined for
interaction with RPA32(172-270) [121]. An additional peptide (269-RERMEKQQVR278) was made from the last segment of RAD52(257-274). The remaining eight peptides
were designed from structural analysis of the self-association domain of RAD52 [119].
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Table A1.1 The sequences RAD52 peptides

Peptide

Amino acid sequence

Peptide 2

42-ALRQRLGPEY-51

Peptide 3

69-HRVINLANEM-78

Peptide 4

81-YNGWAHSITQQ-91

Peptide 5

115-LKDGSYHEDV-124

Peptide 6

141-KARKEAVTDG-150

Peptide 7

167-LDKDYLRS-174

Peptide 8

191-AKRQDKEPSV-200

Peptide 9

253-ATHQRKLRQK-262

Peptide 10

260-RQKQLQQQFR-269

Peptide 11

269-RERMEKQQVR-278

Peptide 12

257-RKLRQKQLQQQFRERMEK-274)

RAD52 self-association

34-EEYQAIQKAL-43

RPA
RPA-binding
binding
domain
region

Peptide 1

Rational for
design

RAD52 short peptides with labeled as P1-P11 with their amino acid sequences.
RAD52(257-274) peptide labeled P12.

118

Screening peptides by FluorIA. Each peptide was added first to a single well of the
FluorIA reaction as an inhibitor at 100 and 10 μM in the same manner described Chapter
2 (Figure A1.1). Additional FluorIA assays were done with peptide combinations to look
for any potential synergetic inhibitory effects. The final concentration of each peptide in
the synergy reaction was 50 μM per well. The layout for the experiment is shown in
Figure A1.2. This experiment will be redone at 100 μM in the future.
Results
In FluorIA, peptide1-11 was added at 10 or 100 μM in the hope of detecting an
inhibitory effect. No signal reduction was detected from any single peptide (Figure A1.1)
or synergy combination of two peptides per well at 50 μM (Figure A1.2).
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Figure A1.1 FluorIA results with RAD52 peptides in singles. Heat map created by R studio
using FluorIA data testing each of the RAD52 peptides as potential SMIs for RAD52:RPA
interaction. The red colored column (column 1) has low RFU readings as a result of inhibition
by Rad52(1-303) and servers as a positive control. The eleven peptides are laid out
horizontally row 1-7 (row 1 and 2) with 10 μM on top and 100 μM in the bottom (row 3 and
4). Column 8 is a negative control.
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Figure A1.2 RAD52 peptide synergy analysis. RAD52 peptides screened as small
molecule inhibitors in pairs according to the FluorIA method described in Chapter 1. The
final concentration of each peptide in a well is 50 µM.
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Appendix II
Additional cell lines for survival analysis with
candidate hits
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Cancer cell lines
1) EUF423 cell line. This cell line contains biallelic truncation of the COOH-terminal
region of both BRCA2 genes also obtained from Dr. Simon Powell along with restored
BRCA2 line. The stable transfection procedures along with culturing conditions for each
cell line are described in Treszezamsky et al., [140].
2) Capan-1 cell lines. Three Capan-1 cell lines were also tested with our hits: BRCA2
mutant Capan-1-neo, empty vector, and is BRCA2-corrected Capan-1-236-BRCA2.
These lines were cultured in DMEM with glutamine, supplemented with 20% FBS,
100U/mL penicillin, 100ug/mL streptomycin.
Western Blot. Cell lysates were separated by 6% SDS-PAGE and BRCA1, BRCA2,
HA-tagged BRCA1 were analyzed by western blots. The Antibodies (Abs) used are:
affinity purified rabbit anti-BRCA1 Ab (Bethyl, #A301-377A), anti-BRCA2 (Ab-1)
mouse monoclonal clone 2B (EMD Millipore, OP95), ECL anti-rabbit IgG-HRP HA (GE
Life Sciences, #NA934), and ECL anti-mouse IgG-HPR (GE Life Sciences, #NA931).
Bands were detected using ECL Clarity (BioRad).
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Figure A2.1 Western blot analysis for BRCA1 and BRCA2 status in HCC1937 and EUFA432 cell lines.
(A) Left: HCC1937 corrected (3rd lane labeled B1) show a band for BRCA1. None was detected in empty
vector (labeled as “V”) or parental line (labeled as “-“). Right: EUFA423 cell line showed a BRCA1 band in
both parental (labeled as “-“) and corrected (labeled as HA-B2). (B and C) Repeats of the EUFA423 lines
listed above with two regular anti-BRCA2 antibodies and two anti-HA antibodies. The results show that the
corrected EUFA423 might have lost its BRCA2 insert plasmid. Upon treatment with P1, P2, and P3; no
difference in survival was observed. The level of BRCA2 expression could be have been sufficient to rescue
cellular phenotype.
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Results
No difference was observed in survival upon treatment of parental or BRCA1/2
plasmid-inserted derivative of Capan-1 or EUFA423 cell lines respectively. A western
blot analysis revealed residual BRCA2 in EUFA423 that might have contributed to equal
survival (Figure A2.1B and C).
Non-cancer CRISPR-generated BRCA2 mutant cell lines.
HeLa-DR cell line that was specifically designed homology-mediated gene conversion
(HR) was used to generate BRCA2 mutants by CRISPR/Cas9 technology. Expression of
BRCA2 in CRISPR-generated BRCA2 mutants. Whole cell lysate was prepared from
each cell line and the levels of BRCA2 protein were examined by western blots. A large
subunit of RPA, p70, was used as loading control. A parental HeLa-DR that contains
wild type BRCA2 and two BRCA2 mutants: g2-10 and g2-37. Each cell line was seeded
at 300 cells/well in 24-well plates and grew overnight. The cells were treated with the
indicated concentrations of MMC for one day. After removing MMC, the cells were
grown in fresh medium for 4-5 days until colonies formed. The cells were stained by
crystal violet, the numbers of colonies were counted, and surviving fraction was
determined. A HeLa-derived cell line, HeLa-DR-13-9 (a generous gift from Dr. Jeffrey
Parvin at the Ohio State University) was used to measure HR activity. Each cell line was
seeded at 3 x 104 cells per well in 12-well plates one day before transfection. The cells
were transfected by the expression plasmid of I-SceI endonclease (a generous gift from
Dr. Maria Jasin at Memorial Sloan Kettering Cancer Center) to induce DSBs. On the
third day of the transfection, the HR activity (scored as GFP positive cells) was
determined by FACS.
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Results
The effect of treatment with P1, P2, and P3 on wt.HeLa (DR) and the BRCA2
mutants’ survival was examined in the same manner described above with cancer cell
lines. However, due to reported higher sensitivity of HeLa cell lines to DNA-damaging
agents treatment with lower doses of concentration series were done. As seen in Figure
A2.2, treatment with P3 showed the most sensitivity compared with treatment of P2
while treatment with P1 impact the wt.HeLa line and higher concentration series of it was
needed to observe the effect.
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Figure A2.2 CRISPR-generated BRCA2 mutants HeLa-DR, BRCA2 mutants. The
g2-10, BRCA2 mutant g2-37 were treated with increasing concentrations of (A) P1, (B)
P2 and (C) P3 and incubated for three days at 37°C. PrestoBlue reagent was used to
assess the viabilities of the treated cells as detailed in Material and methods, and the
obtained results were normalized to vehicle control.
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Appendix III
Development of SSA activity assay
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Introduction
Sugiyama and co-workers exploited the selective binding of DAPI dsDNA to
fluorescently follow the annealing activity of a Rad52:RPA complex in the presence of a
heat-denatured DNA plasmid [75]. Their work demonstrated the important role for RPA
in promoting SSA activity of RAD52. Given our great interest in RAD52 interaction with
RPA, we developed a similar but more robust SSA activity assay employing longer DNA
in the reaction, human proteins, and a much more sensitive method of detection (SYBR
Dyes) that exhibits >1000-fold fluorescence enhancement upon binding to nucleic acids
and has a high quantum yield (~0.6) upon binding to ds or ssDNA [141].
Method
Purified 8D-RPA and RAD52 (Figure A3.1 A and B respectively) were used in this
assay. Purification for each followed the same protocol detailed in Chapter 2. A 50 ng of
pBlueScript KS(+/-) plasmid DNA linearized by Scal (dsDNA) and heat-denatured
linearized (hdDNA). The hdDNA was preincubated with 8D-RPA for one hour before the
addition of RAD52 in a 1:2 ratio. The products were separated by 1% agarose gel (100
voltage for 1 hour and 40 minutes in 1x TAE buffer). SYBR stains (SYBR Green for
dsDNA and SYBR Gold for both dsDNA and ssDNA, Molecular Probes) were diluted in
1x TAE buffer according to manufacturer instructions and used to stain the gels for 20
minutes before washing 2x with ddH2O and imaging with Safe Imager 2.0 (Invitrogen).
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Figure A3.1 SDS-PAGE gel of purified protein constructs. A) Purified
hetero-trimeric 8D-RPA. B) Different constructs of RAD52 shown from
left to right: full length RAD52, full-length RAD52 with an EGFP tag, and
RAD52(1-212) construct.
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Results
We observed the characteristic hdDNA band at about ~2900 base pair (Figure A3.2, red
box) disappeared in the presence of 8D-RPA and a band above the 10,000 base-pair mark
appeared, (Figure A3.2, blue box), indicating multiple RPAs binding to the ssDNA.
RAD52:DNA cpmplex have been noted to accumulate as large molecular weight
aggregates in the gel wells [142]. Our result confirms this phenomoneon, as seen in the last
four lanes containing decreasing concentrations of RAD52 added to an RPA-bound
ssDNA. Nevertheless, we demonstrated the annealing of the plasmid as indicated by the
dose-related reappearance of the dsDNA at its expected size of 3500 bp. We will use this
assay to test the effect of RPA phosphorylation and candidate SMIs on RAD52 activity.
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Figure A3.2 RAD52 SSA assay. Gel based assay using 8D-RPA and RAD52.
The gel was stained with SYBR Gold and our interpretation was confirmed with
SYBR Green (not shown).
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Appendix IV
8D-RPA SAXS analysis
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Introduction
RPA is phosphorylated in a cell cycle-dependent manner to regulate its interaction
with DNA and protein partners. Specific phosphorylation events on multiple serine
residues of RPA32 subunit as this site is a hub for PPI, including RAD52. An RPA
phosphmimic was created by Wolds and co-workers to mimic hyperphosphorylated RPA.
It contains the following mutations on RPA32: S8D, S11D, S12D, S13D, T21D, S25D,
S29D, and S33D.
It has not been possible to obtain full structural data on RPA using crystallography or
NMR due to flexible nature of the regions linking the different domains. Here we used
SAXS to analyze an overall low-resolution structural measurement of 8DRPA.
Methods
The plasmid for 8D RPA was a generous gift from Dr. Marc Wolds. Transformation
was done into Rosetta2(DE3). Expression and growth were the same as described for
RPA in chapter 2 with the addition of purification using size exclusion column with 300
mM KCl in HI-0 buffer described in Chapter 2. Fractions were then collected
individually and assessed by DLS for monodispersity.
Two monodispersed samples were obtained, and concentrations were determined by
NanoDrop1000. The two samples were concentrated separately using spin concentrators
(30,000 MWCO) achieving 6 mg/mL and 8 mg/mL. The flow-through resulting from the
concentration process was collected to use as blank buffer in SAXS analysis. Column
void volume is the buffer volume before the elution of the protein in the size exclusion
purification step was also collected for the same purpose.
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Images were collected for 1.5 hours at room temperature on Rigaku BioSAXS 1000
system with an FR-E rotating anode X-ray generator (λ= 1.54 Å). Resulting data were
processed using Automated Analysis Pipline in SAXSLab software which provides a
GUI for the ARSAS Package (Rigaku). The buffer effect was automatically subtracted by
the software and the Guinier plot, radius of gyration, molecular weight and volume, pair
distribution function, Kratky plot, an infinite dilution scattering curve, and ab initio bead
model fits to the data were calculated as well. Finally, Dmax was calculated from the Xintercept of the P(r) curve were calculated. Models were generated using PyMOL
(SchrÖdinger, LLC).
Results and discussion
SAXS is a low-resolution technique that is of great value to obtain an overall shape
and dimension data that can be paired with higher resolution structural data from
crystallography or NMR techniques. It is also a feasible technique to analyze full-length
proteins in solution [143]. At the time of this investigation, we had the 8DRPA
expression and purification resolved and therefore was used in the SAXS analysis. We
anticipated no difference from the wild-type RPA. The data were collected over two
concentrations: 6 and 8mg/mL that were checked for monodispersity using DLS.
The scattering pattern indicate q of about 0.2 demonstrating less noise and good
quality data at the concentrations analyzed (Figure A4.1 A). Using the Guinier
approximation and scattering data, the radius of gyration (Rg) was obtained and reported
in table A4.1. Kratky plot shown in figure A3.1B indicates partial folding as the curves
increase at higher q values after reaching a peak. Finally, maximum dimensions (Dmax)
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(Table A4.1) was calculated from the probability distribution function, P(r), plot (Figure
A4.1C). The maximum dimension for 8DRPA seems to be around 175 Å.
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Figure A4.1 SAXS profile data for 8DRPA. A) SAXS scattering, B) Kratky plot, C)
probability distribution of 8DRPA at the two different concentrations analyzed.
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Table A4.1 Predictions of 8DRPA dimension values.

8DRPA concentration (mg/mL)

Rg

Dmax

6

49

166

8

51

173

SAXSLab software calculation of the radius of gyration (Rg) using the SAXS
scattering pattern and maximum dimension (Dmax) using from the x-intercept of the
P(r) curve.
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The relative topology of 8DRPA is demonstrated by the Ab initio bead models that
were fit to the P(r) function. The molecular envelop shows an extended structure for the
most parts of the protein with semi-globular conformation in most of the central and
terminal region (Figure A4.2).
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Front view

Side view
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Figure A4.2 SAXS model for 8DRPA.
Ab initio bead models to predict the molecular envelop of full-length 8DRPA.
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